

AP20 Rec'd PCT/PTO 04 MAY 2006

5

**METHODS OF USING AND COMPOSITIONS COMPRISING
A JNK INHIBITOR FOR THE TREATMENT AND MANAGEMENT OF
ASBESTOS-RELATED DISEASES AND DISORDERS**

1. FIELD OF INVENTION

This invention relates to methods of treating, preventing and/or managing an asbestos-related disease or disorder, which comprise the administration of a JNK Inhibitor alone or in combination with known therapeutics. The invention also relates to pharmaceutical compositions and dosing regimens. In particular, the invention encompasses the use of a JNK Inhibitor in conjunction with surgery or radiation therapy and/or other standard therapies for diseases associated with asbestos poisoning.

2. BACKGROUND OF THE INVENTION

15 2.1 ASBESTOS-RELATED DISEASES OR DISORDERS

Several million individuals worldwide were exposed to asbestos in the mining of ore or the manufacture and use of asbestos products. D. R. Aberle, *Seminars in Roentgenology*, 24 (2): 118, 1991. Given the long latency for the development of many pathological consequences of asbestos, asbestos-related diseases will likely dominate the field of occupational and environmental diseases for some time. Benign asbestos-related diseases and disorders include asbestosis, pleural effusion, pleural plaques, diffuse pleural thickening, and rounded atelectasis. C. A. Staples, *Radiologic Clinics of North America*, 30 (6): 1191, 1992. Malignant asbestos-related diseases include malignant pleural effusion, pleural or peritoneal mesothelioma, and bronchogenic carcinoma. Merck Index, 1999 (17th ed.), 645 and 651.

Asbestosis (interstitial fibrosis) is defined as diffuse lung fibrosis due to the inhalation of asbestos fibers. C. A. Staples, *Radiologic Clinics of North America*, 30 (6): 1195, 1992. It is one of the major causes of occupationally related lung damage. Merck Index, 1999 (17th ed.), 622. Asbestosis characteristically occurs following a latent period of 15-20 years, with a progression of disease even after exposure has ceased, but rarely occurs in the absence of pleural plaques. C. Peacock, *Clinical Radiology*, 55: 425, 2000. Fibrosis first arises in and around the respiratory bronchioles, predominating in the

BEST AVAILABLE COPY

5 subpleural portions of the lung in the lower lobes, and then progresses centrally. C. A. Staples, *Radiologic Clinics of North America*, 30 (6): 1195, 1992. Asbestosis may cause an insidious onset of progressive dyspnea in addition to a dry cough. The incidence of lung cancer is increased in smokers with asbestosis, and a dose-response relationship has been observed. Merck Index, 1999 (17th ed.), 623.

10 Another asbestos-related disorder is pleural effusion. Pleural effusions are often the earliest manifestation of asbestos-related disease. C. A. Staples, *Radiologic Clinics of North America*, 30 (6): 1192, 1992. People exposed to asbestos can develop an exudative pleural effusion five to 20 years after exposure. Merck Index, 1999 (17th ed.), 645; C. A. Staples, *Radiologic Clinics of North America*, 30 (6): 1192, 1992; and C.
15 Peacock, *Clinical Radiology*, 55: 427, 2000. Effusion may follow short exposure, but more often follows intermediate exposure of about 10 to 15 years. The clinical picture in benign asbestos-related pleural effusion varies from asymptomatic patients to patients with an acute episode of pleuritic chest pain and pyrexia. *Id.*, 426. The mechanism is unknown, but it is assumed that the fibers migrate from the lungs to the pleura and
20 induce an inflammatory response. In most people, effusions clear after three to four months, but can persist or recur over several years. *Id.* As the effusion resolves, many develop diffuse pleural thickening. *Id.*

Pleural plaques are a common manifestation of asbestos exposure, typically occurring after a latent period of approximately 20-30 years. C. A. Staples, *Radiologic*
25 *Clinics of North America*, 30 (6): 1191, 1992; and C. Peacock, *Clinical Radiology*, 55: 423, 2000. Histologically, pleural plaques consist of acellular collagen bundles that form a basket-weave pattern, which almost exclusively involves the parietal pleura. C. A. Staples, *Radiologic Clinics of North America*, 30 (6): 1191, 1992. The precise pathogenesis of pleural plaques remains undetermined, although some have assumed that
30 they are caused by the mechanical effect of asbestos fibers piercing the visceral pleura. C. Peacock, *Clinical Radiology*, 55: 425, 2000. Currently, however, the fibers are believed to be transported to the parietal pleura via lymphatic channels, where they incite an inflammatory response. *Id.* Plaques slowly grow over time, even after cessation of exposure, but they are not considered premalignant. *Id.* Calcification occurs later, often
35 30-40 years following exposure. *Id.*, 424; and C. A. Staples, *Radiologic Clinics of North*

5 *America*, 30 (6): 1191, 1992. Although there is a significant correlation between the severity of the pleural disease and that of asbestosis, pleural plaques tend to occur in isolation without any other manifestations of asbestos-related diseases. C. Peacock, *Clinical Radiology*, 55: 425, 2000.

10 Another common manifestation of asbestos exposure is diffuse pleural thickening. C. A. Staples, *Radiologic Clinics of North America*, 30 (6): 1193, 1992. Usually, the latent period is approximately 15 years. Diffuse pleural thickening is less specific for asbestos exposure than the presence of pleural plaques, since thickening also may be seen following TB pleuritis, hemothorax and empyema. C. Peacock, *Clinical Radiology*, 55: 427, 2000. The most common symptom is dyspnea. The pathogenesis is
15 unclear, but it is believed to be due to inflammation and fibrosis of the visceral pleural lymphatics, and it has been considered an extension of parenchymal fibrosis. *Id.* Development of diffuse pleural thickening has a similar time-line as plaque formation. Thickening is a common concomitant finding to asbestosis, with a reported associated incidence of 10%. *Id.*

20 Another disease associated with asbestos exposure is round atelectasis, which refers to atelectatic lung adjacent to pleural thickening with characteristic in-drawing of bronchi and vessels. T. Wallace, *Diagnostic Cytopathology*, 8 (6): 617, 1992; C. Peacock, *Clinical Radiology*, 55: 429, 2000; and C. A. Staples, *Radiologic Clinics of North America*, 30 (6): 1193, 1992. It is also known as folded lung, pulmonary
25 pseudotumor, pleuroma or Blesovsky syndrome. *Id.* The presence of the effusion has been postulated to cause passive atelectasis, with infolding of the lung resulting in invagination of the adjacent pleura. *Id.* This process causes tethering, which prevents reexpansion of the lung upon resolution of the effusion and which causes round atelectasis. *Id.* An alternative explanation is that an insult to the pleura leads to
30 localized inflammation and fibrosis, which results in volume loss and buckling of the underlying lung. *Id.* The lingula is the most common site, followed by the middle and then the lower lobes, although lesions may be multiple and bilateral. *Id.*

 Mesothelioma is a malignant pleural or peritoneal neoplasm that is usually associated with occupational exposure to asbestos. Merck Index, 1999 (17th ed.), 645.
35 The clinical latency period between asbestos exposure and mesothelioma development is

5 typically 15-40 years. *Id.*, 623; and C. Peacock, *Clinical Radiology*, 55: 427, 2000. As a result, the number of mesothelioma patients has continued to rise despite decreased asbestos production. JMW van Haarst *et al.*, *British Journal of Cancer*, 86: 342, 2002. The common symptoms are chest pain, dyspnea, cough, weight loss, weakness and increased sputum production. Merck Index, 1999 (17th ed.), 645. The tumor gradually
10 encases the lungs, invades the chest wall, and produces pleural effusion in about 75% of patients. *Id.* The prognosis is dismal, with poor response to radial surgery, chemotherapy, or radiation therapy. *Id.*

The causal relationship between bronchogenic carcinoma and asbestos exposure is well accepted. Merck Index, 1999 (17th ed.), 651; and D. R. Aberle, *Seminars in*
15 *Roentgenology*, 24 (2): 124, 1991. It shows a dose response at occupational exposure levels. *Id.* The relative risk of lung cancer in asbestos workers increases multiplicatively with combined cigarette smoking, and asbestos-related interstitial disease is often associated with it. *Id.* Lung cancer has been also reported in individuals without interstitial lung disease who are exposed to asbestos. *Id.*

20 2.2 CONVENTIONAL TREATMENTS

The primary strategy for dealing with asbestos-related diseases or disorders is prevention, with the worldwide elimination of asbestos use and with the replacement of asbestos by safe synthetic products. No treatment for asbestosis is known to be effective. Mesothelioma is very difficult to treat, and no standard therapy for its treatment currently
25 exists. Kaiser LR., *Semin Thorac Cardiovasc Surg.* Oct., 9 (4): 383-90, 1997. The methods of chemotherapy, radiation therapy, and surgery have all been used with little improvement in overall survival, although trimodality therapy that involves a combination of all three treatments has been shown to improve survival in selected patients. *Id.*

30 The two primary surgical interventions used to treat mesothelioma are pleurectomy and extrapleural pneumonectomy (EPP). Pleurectomy usually is a palliative procedure to relieve chest wall pain and prevent recurrent pleural effusions by stripping off the visceral and parietal pleura. C. Turton, *British Journal of Hospital Medicine*, 23(3): 249, 1980. EPP is an en bloc resection of the parietal and mediastinal pleura,
35 lung, hemi-diaphragm, and ipsilateral pericardium to remove all gross disease.

5 Sugarbaker DJ, *Ann Surg.*, 224(3):288-94, 1996. EPP is indicated for stage I tumors with no involvement of the mediastinal lymph nodes. EPP is a technically demanding surgery with significant morbidity. The surgical complications of pleurectomy and EPP include pneumonia, bronchopleural fistulae, bronchial leaks, empyema, chylothorax, respiratory insufficiency, myocardial infarction, congestive heart failure, hemorrhage,
10 cardiac volvulus, subcutaneous emphysema, incomplete tumor removal, and vocal cord paralysis. *Id.*

Radiotherapy usually is palliative or adjunctive to surgery. C. Turton, *British Journal of Hospital Medicine*, 23(3): 249, 1980. Brachytherapy, intrapleural implantation of radioactive isotopes, delivers high-dose radiation locally to the pleural
15 space and is used for recurrent pleural effusions. *Id.* Postoperative radiation therapy can prevent recurrence within chest wall incision sites. Complications of radiotherapy include nausea and vomiting, radiation hepatitis, esophagitis, myelitis, myocarditis, and pneumonitis with deterioration of pulmonary function.

Photodynamic therapy is an adjuvant treatment in patients with surgically treated
20 pleural malignancies. P. Baas, *Br. J. Cancer.*, 76(6): 819-26, 1997. A light-activated photosensitizing drug is instilled intrapleurally and is excited by light of a certain wavelength to produce oxygen free radicals that cause tumor necrosis. *Id.*

Response to chemotherapy has been disappointing because comparison of chemotherapies has been difficult. Intrapleural instillations of antibiotics such as
25 mepacrine, thiotepa, and tetracycline have been reported to be sometimes successful. C. Turton, *British Journal of Hospital Medicine* 23(3): 247, 1980. Various cytotoxic drugs including mustine have been instilled into the pleural cavity. *Id.* Medications presently used during the treatment of mesothelioma include GM-CSF, doxorubicin, gemcitabine, cisplatin, vinblastine, adriamycin, bleomycin, hyaluronidase, methotrexate and
30 mitomycin. JMW van Haarst *et al.*, *British Journal of Cancer*, 86: 342-345, 2002. However, patients rarely obtain complete relief. Chemotherapy results in less than 20% response and has not yet been shown to improve survival in patients with mesothelioma. *Id.* Therefore, there remains a need for safe and effective methods of treating and managing mesothelioma and other diseases associated with exposure to asbestos.

- 5 Citation of any reference in Section 2 of this application is not an admission that the reference is prior art to the application.

3. SUMMARY OF THE INVENTION

This invention encompasses methods for treating, preventing and/or managing asbestos- related diseases or disorders, which comprise administering to a patient in need
10 thereof a therapeutically or prophylactically effective amount of a JNK Inhibitor, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.

Another embodiment of the invention encompasses the use of one or more JNK Inhibitors in combination with other therapeutics typically used to treat or prevent
15 asbestos-related diseases or disorders such as, but not limited to, anti-cancer agents, antibiotics, anti-inflammatory agents, cytokines, steroids, immunomodulatory agents, immunosuppressive agents, and other known therapeutics.

Yet another embodiment of the invention encompasses the use of one or more JNK Inhibitors in combination with conventional therapies used to treat, prevent or
20 manage asbestos-related diseases or disorders including, but not limited to, chemotherapy, surgery, radiation therapy and photodynamic therapy.

The invention further encompasses pharmaceutical compositions, single unit dosage forms, and kits suitable for use in treating, preventing and/or managing asbestos-related diseases or disorders, which comprise one or more JNK Inhibitors, or a
25 pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, and one or more additional active agents.

3.1 DEFINITIONS

As used herein, the term "patient" means an animal (*e.g.*, cow, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig), preferably a mammal
30 such as a non-primate or a primate (*e.g.*, monkey or human), most preferably a human.

"Alkyl" means a saturated straight chain or branched non-cyclic hydrocarbon having from 1 to 10 carbon atoms. "Lower alkyl" means alkyl, as defined above, having from 1 to 4 carbon atoms. Representative saturated straight chain alkyls include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl, -n-nonyl and -n-decyl;

5 while saturated branched alkyls include -isopropyl, -*sec*-butyl, -isobutyl, -*tert*-butyl, -isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylpentyl, 2,2-dimethylhexyl, 3,3-dimethylpentyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylpentyl, 3-ethylpentyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, 2-methyl-4-ethylpentyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2-methyl-4-ethylhexyl, 2,2-diethylpentyl, 3,3-diethylhexyl, 2,2-diethylhexyl, 3,3-diethylhexyl and the like.

15 An "alkenyl group" or "alkylidene" mean a straight chain or branched non-cyclic hydrocarbon having from 2 to 10 carbon atoms and including at least one carbon-carbon double bond. Representative straight chain and branched (C₂-C₁₀) alkenyls include -vinyl, -allyl, -1-butenyl, -2-butenyl, -isobutylenyl, -1-pentenyl, -2-pentenyl, -3-methyl-1-butenyl, -2-methyl-2-butenyl, -2,3-dimethyl-2-butenyl, -1-hexenyl, -2-hexenyl, -3-hexenyl, -1-heptenyl, -2-heptenyl, -3-heptenyl, -1-octenyl, -2-octenyl, -3-octenyl, -1-nonenyl, -2-nonenyl, -3-nonenyl, -1-decenyl, -2-decenyl, -3-decenyl and the like. An alkenyl group can be unsubstituted or substituted. A "cyclic alkylidene" is a ring having from 3 to 8 carbon atoms and including at least one carbon-carbon double bond, wherein the ring can have from 1 to 3 heteroatoms.

25 An "alkynyl group" means a straight chain or branched non-cyclic hydrocarbon having from 2 to 10 carbon atoms and including at least one carbon-carbon triple bond. Representative straight chain and branched (C₂-C₁₀) alkynyls include -acetylenyl, -propynyl, -1-butyne, -2-butyne, -1-pentyne, -2-pentyne, -3-methyl-1-butyne, -4-pentyne, -1-hexyne, -2-hexyne, -5-hexyne, -1-heptyne, -2-heptyne, -6-heptyne, -1-octyne, -2-octyne, -7-octyne, -1-nonyne, -2-nonyne, -8-nonyne, -1-decynyl, -2-decynyl, -9-decynyl, and the like. An alkynyl group can be unsubstituted or substituted.

The terms "Halogen" and "Halo" mean fluorine, chlorine, bromine or iodine.

"Haloalkyl" means an alkyl group, wherein alkyl is defined above, substituted with one or more halogen atoms.

35 "Keto" means a carbonyl group (*i.e.*, C=O).

5 “Acyl” means an -C(O)alkyl group, wherein alkyl is defined above, including -C(O)CH₃, -C(O)CH₂CH₃, -C(O)(CH₂)₂CH₃, -C(O)(CH₂)₃CH₃, -C(O)(CH₂)₄CH₃, -C(O)(CH₂)₅CH₃, and the like.

 “Acyloxy” means an -OC(O)alkyl group, wherein alkyl is defined above, including -OC(O)CH₃, -OC(O)CH₂CH₃, -OC(O)(CH₂)₂CH₃, -OC(O)(CH₂)₃CH₃, -
10 OC(O)(CH₂)₄CH₃, -OC(O)(CH₂)₅CH₃, and the like.

 “Ester” means and -C(O)Oalkyl group, wherein alkyl is defined above, including -C(O)OCH₃, -C(O)OCH₂CH₃, -C(O)O(CH₂)₂CH₃, -C(O)O(CH₂)₃CH₃, -C(O)O(CH₂)₄CH₃, -C(O)O(CH₂)₅CH₃, and the like.

 “Alkoxy” means -O-(alkyl), wherein alkyl is defined above, including -OCH₃, -
15 OCH₂CH₃, -O(CH₂)₂CH₃, -O(CH₂)₃CH₃, -O(CH₂)₄CH₃, -O(CH₂)₅CH₃, and the like.

 “Lower alkoxy” means -O-(lower alkyl), wherein lower alkyl is as described above.

 “Alkoxyalkoxy” means -O-(alkyl)-O-(alkyl), wherein each alkyl is independently an alkyl group defined above, including -OCH₂OCH₃, -OCH₂CH₂OCH₃, -OCH₂CH₂OCH₂CH₃, and the like.

20 “Alkoxy carbonyl” means -C(=O)O-(alkyl), wherein alkyl is defined above, including -C(=O)O-CH₃, -C(=O)O-CH₂CH₃, -C(=O)O-(CH₂)₂CH₃, -C(=O)O-(CH₂)₃CH₃, -C(=O)O-(CH₂)₄CH₃, -C(=O)O-(CH₂)₅CH₃, and the like.

 “Alkoxy carbonylalkyl” means -(alkyl)-C(=O)O-(alkyl), wherein each alkyl is independently defined above, including -CH₂-C(=O)O-CH₃, -CH₂-C(=O)O-CH₂CH₃, -
25 CH₂-C(=O)O-(CH₂)₂CH₃, -CH₂-C(=O)O-(CH₂)₃CH₃, -CH₂-C(=O)O-(CH₂)₄CH₃, -CH₂-C(=O)O-(CH₂)₅CH₃, and the like.

 “Alkoxyalkyl” means -(alkyl)-O-(alkyl), wherein each alkyl is independently an alkyl group defined above, including -CH₂OCH₃, -CH₂OCH₂CH₃, -(CH₂)₂OCH₂CH₃, -(CH₂)₂O(CH₂)₂CH₃, and the like.

30 “Aryl” means a carbocyclic aromatic group containing from 5 to 10 ring atoms. Representative examples include, but are not limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, pyridinyl and naphthyl, as well as benzo-fused carbocyclic moieties including 5,6,7,8-tetrahydronaphthyl. A carbocyclic aromatic group can be unsubstituted or substituted. In one embodiment, the carbocyclic aromatic group is a
35 phenyl group.

5 “Aryloxy” means -O-aryl group, wherein aryl is as defined above. An aryloxy group can be unsubstituted or substituted. In one embodiment, the aryl ring of an aryloxy group is a phenyl group

 “Arylalkyl” means -(alkyl)-(aryl), wherein alkyl and aryl are as defined above, including -(CH₂)phenyl, -(CH₂)₂phenyl, -(CH₂)₃phenyl, -CH(phenyl)₂, -CH(phenyl)₃, -
10 (CH₂)tolyl, -(CH₂)anthracenyl, -(CH₂)fluorenyl, -(CH₂)indenyl, -(CH₂)azulenyl, -(CH₂)pyridinyl, -(CH₂)naphthyl, and the like.

 “Arylalkyloxy” means -O-(alkyl)-(aryl), wherein alkyl and aryl are defined above, including -O-(CH₂)₂phenyl, -O-(CH₂)₃phenyl, -O-CH(phenyl)₂, -O-CH(phenyl)₃, -O-(CH₂)tolyl, -O-(CH₂)anthracenyl, -O-(CH₂)fluorenyl, -O-(CH₂)indenyl, -O-
15 (CH₂)azulenyl, -O-(CH₂)pyridinyl, -O-(CH₂)naphthyl, and the like.

 “Aryloxyalkyl” means -(alkyl)-O-(aryl), wherein alkyl and aryl are defined above, including -CH₂-O-(phenyl), -(CH₂)₂-O-phenyl, -(CH₂)₃-O-phenyl, -(CH₂)-O-tolyl, -(CH₂)-O-anthracenyl, -(CH₂)-O-fluorenyl, -(CH₂)-O-indenyl, -(CH₂)-O-azulenyl, -(CH₂)-O-pyridinyl, -(CH₂)-O-naphthyl, and the like.

20 “Cycloalkyl” means a monocyclic or polycyclic saturated ring having carbon and hydrogen atoms and having no carbon-carbon multiple bonds. Examples of cycloalkyl groups include, but are not limited to, (C₃-C₇)cycloalkyl groups, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, and saturated cyclic and bicyclic terpenes. A cycloalkyl group can be unsubstituted or substituted. In one embodiment,
25 the cycloalkyl group is a monocyclic ring or bicyclic ring.

 “Cycloalkyloxy” means -O-(cycloalkyl), wherein cycloalkyl is defined above, including -O-cyclopropyl, -O-cyclobutyl, -O-cyclopentyl, -O-cyclohexyl, -O-cycloheptyl and the like.

 “Cycloalkylalkyloxy” means -O-(alkyl)-(cycloalkyl), wherein cycloalkyl and alkyl are defined above, including -O-CH₂-cyclopropyl, -O-(CH₂)₂-cyclopropyl, -O-(CH₂)₃-cyclopropyl, -O-(CH₂)₄-cyclopropyl, O-CH₂-cyclobutyl, O-CH₂-cyclopentyl, O-CH₂-cyclohexyl, O-CH₂-cycloheptyl, and the like.
30

 “Aminoalkoxy” means -O-(alkyl)-NH₂, wherein alkyl is defined above, such as -O-CH₂-NH₂, -O-(CH₂)₂-NH₂, -O-(CH₂)₃-NH₂, -O-(CH₂)₄-NH₂, -O-(CH₂)₅-NH₂, and the like.
35

5 “Mono-alkylamino” means -NH(alkyl), wherein alkyl is defined above, such as -NHCH₃, -NHCH₂CH₃, -NH(CH₂)₂CH₃, -NH(CH₂)₃CH₃, -NH(CH₂)₄CH₃, -NH(CH₂)₅CH₃, and the like.

 “Di-alkylamino” means -N(alkyl)(alkyl), wherein each alkyl is independently an alkyl group defined above, including -N(CH₃)₂, -N(CH₂CH₃)₂, -N((CH₂)₂CH₃)₂,
10 -N(CH₃)(CH₂CH₃), and the like.

 “Mono-alkylaminoalkoxy” means -O-(alkyl)-NH(alkyl), wherein each alkyl is independently an alkyl group defined above, including -O-(CH₂)-NHCH₃, -O-(CH₂)-NHCH₂CH₃, -O-(CH₂)-NH(CH₂)₂CH₃, -O-(CH₂)-NH(CH₂)₃CH₃, -O-(CH₂)-NH(CH₂)₄CH₃, -O-(CH₂)-NH(CH₂)₅CH₃, -O-(CH₂)₂-NHCH₃, and the like.

15 “Di-alkylaminoalkoxy” means -O-(alkyl)-N(alkyl)(alkyl), wherein each alkyl is independently an alkyl group defined above, including -O-(CH₂)-N(CH₃)₂, -O-(CH₂)-N(CH₂CH₃)₂, -O-(CH₂)-N((CH₂)₂CH₃)₂, -O-(CH₂)-N(CH₃)(CH₂CH₃), and the like.

 “Arylamino” means -NH(aryl), wherein aryl is defined above, including -NH(phenyl), -NH(tolyl), -NH(anthracenyl), -NH(fluorenyl), -NH(indenyl), -
20 NH(azulenyl), -NH(pyridinyl), -NH(naphthyl), and the like.

 “Arylalkylamino” means -NH-(alkyl)-(aryl), wherein alkyl and aryl are defined above, including -NH-CH₂-(phenyl), -NH-CH₂-(tolyl), -NH-CH₂-(anthracenyl), -NH-CH₂-(fluorenyl), -NH-CH₂-(indenyl), -NH-CH₂-(azulenyl), -NH-CH₂-(pyridinyl), -NH-CH₂-(naphthyl), -NH-(CH₂)₂-(phenyl) and the like.

25 “Alkylamino” means mono-alkylamino or di-alkylamino as defined above, such as -N(alkyl)(alkyl), wherein each alkyl is independently an alkyl group defined above, including -N(CH₃)₂, -N(CH₂CH₃)₂, -N((CH₂)₂CH₃)₂, -N(CH₃)(CH₂CH₃) and -N(alkyl)(alkyl), wherein each alkyl is independently an alkyl group defined above, including -N(CH₃)₂, -N(CH₂CH₃)₂, -N((CH₂)₂CH₃)₂, -N(CH₃)(CH₂CH₃) and the like.

30 “Cycloalkylamino” means -NH-(cycloalkyl), wherein cycloalkyl is as defined above, including -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -NH-cyclohexyl, -NH-cycloheptyl, and the like.

 “Carboxyl” and “carboxy” mean -COOH.

 “Cycloalkylalkylamino” means -NH-(alkyl)-(cycloalkyl), wherein alkyl and
35 cycloalkyl are defined above, including -NH-CH₂-cyclopropyl, -NH-CH₂-cyclobutyl,

5 -NH-CH₂-cyclopentyl, -NH-CH₂-cyclohexyl, -NH-CH₂-cycloheptyl, -NH-(CH₂)₂-cyclopropyl and the like.

"Aminoalkyl" means -(alkyl)-NH₂, wherein alkyl is defined above, including CH₂-NH₂, -(CH₂)₂-NH₂, -(CH₂)₃-NH₂, -(CH₂)₄-NH₂, -(CH₂)₅-NH₂ and the like.

"Mono-alkylaminoalkyl" means -(alkyl)-NH(alkyl), wherein each alkyl is
 10 independently an alkyl group defined above, including -CH₂-NH-CH₃, -CH₂-NHCH₂CH₃, -CH₂-NH(CH₂)₂CH₃, -CH₂-NH(CH₂)₃CH₃, -CH₂-NH(CH₂)₄CH₃, -CH₂-NH(CH₂)₅CH₃, -(CH₂)₂-NH-CH₃, and the like.

"Di-alkylaminoalkyl" means -(alkyl)-N(alkyl)(alkyl), wherein each alkyl is independently an alkyl group defined above, including -CH₂-N(CH₃)₂, -CH₂-N(CH₂CH₃)₂, -CH₂-N((CH₂)₂CH₃)₂, -CH₂-N(CH₃)(CH₂CH₃), -(CH₂)₂-N(CH₃)₂, and the
 15 like.

"Heteroaryl" means an aromatic heterocycle ring of 5- to 10 members and having at least one heteroatom selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom, including both mono- and bicyclic ring systems. Representative
 20 heteroaryls are triazolyl, tetrazolyl, oxadiazolyl, pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinoliny, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnoliny, phthalazinyl, quinazolinyl, pyrimidyl, oxetanyl, azepinyl, piperazinyl, morpholinyl, dioxanyl, thietanyl and
 25 oxazolyl.

"Heteroarylalkyl" means -(alkyl)-(heteroaryl), wherein alkyl and heteroaryl are defined above, including -CH₂-triazolyl, -CH₂-tetrazolyl, -CH₂-oxadiazolyl, -CH₂-pyridyl, -CH₂-furyl, -CH₂-benzofuranyl, -CH₂-thiophenyl, -CH₂-benzothiophenyl, -CH₂-quinoliny, -CH₂-pyrrolyl, -CH₂-indolyl, -CH₂-oxazolyl, -CH₂-benzoxazolyl, -CH₂-imidazolyl, -CH₂-benzimidazolyl, -CH₂-thiazolyl, -CH₂-benzothiazolyl, -CH₂-isoxazolyl, -CH₂-pyrazolyl, -CH₂-isothiazolyl, -CH₂-pyridazinyl, -CH₂-pyrimidinyl, -CH₂-pyrazinyl, -CH₂-triazinyl, -CH₂-cinnoliny, -CH₂-phthalazinyl, -CH₂-quinazolinyl, -CH₂-pyrimidyl, -CH₂-oxetanyl, -CH₂-azepinyl, -CH₂-piperazinyl, -CH₂-morpholinyl, -CH₂-dioxanyl, -CH₂-thietanyl, -CH₂-oxazolyl, -(CH₂)₂-triazolyl, and the like.
 30

5 “Heterocycle” means a 5- to 7-membered monocyclic, or 7- to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms can be optionally oxidized, and the nitrogen heteroatom can be optionally quaternized, including bicyclic rings in which any of the
10 above heterocycles are fused to a benzene ring. The heterocycle can be attached via any heteroatom or carbon atom. Heterocycles include heteroaryls as defined above. Representative heterocycles include morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl,
15 tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.

 “Heterocycle fused to phenyl” means a heterocycle, wherein heterocycle is defined as above, that is attached to a phenyl ring at two adjacent carbon atoms of the phenyl ring.

20 “Heterocycloalkyl” means -(alkyl)-(heterocycle), wherein alkyl and heterocycle are defined above, including -CH₂-morpholinyl, -CH₂-pyrrolidinonyl, -CH₂-pyrrolidinyl, -CH₂-piperidinyl, -CH₂-hydantoinyl, -CH₂-valerolactamyl, -CH₂-oxiranyl, -CH₂-oxetanyl, -CH₂-tetrahydrofuranyl, -CH₂-tetrahydropyranyl, -CH₂-tetrahydropyridinyl, -CH₂-tetrahydropyrimidinyl, -CH₂-tetrahydrothiophenyl, -CH₂-tetrahydrothiopyranyl,
25 -CH₂-tetrahydropyrimidinyl, -CH₂-tetrahydrothiophenyl, -CH₂-tetrahydrothiopyranyl, and the like.

 The term “substituted” as used herein means any of the above groups (*i.e.*, aryl, arylalkyl, heterocycle and heterocycloalkyl) wherein at least one hydrogen atom of the moiety being substituted is replaced with a substituent. In one embodiment, each carbon
30 atom of the group being substituted is substituted with no more than two substituents. In another embodiment, each carbon atom of the group being substituted is substituted with no more than one substituent. In the case of a keto substituent, two hydrogen atoms are replaced with an oxygen which is attached to the carbon via a double bond. Substituents include halogen, hydroxyl, alkyl, haloalkyl, mono- or di-substituted aminoalkyl,
35 alkyloxyalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, -NR_aR_b, -NR_aC(=O)R_b,

- 5 -NR_aC(=O)NR_aR_b, -NR_aC(=O)OR_b, -NR_aSO₂R_b, -OR_a, -C(=O)R_a C(=O)OR_a
 -C(=O)NR_aR_b, -OC(=O)R_a, -OC(=O)OR_a, -OC(=O)NR_aR_b, -NR_aSO₂R_b, or a radical of
 the formula -Y-Z-R_a where Y is alkanediyl, or a direct bond, Z is -O-, -S-, -N(R_b)-,
 -C(=O)-, -C(=O)O-, -OC(=O)-, -N(R_b)C(=O)-, -C(=O)N(R_b)- or a direct bond, wherein
 R_a and R_b are the same or different and independently hydrogen, amino, alkyl, haloalkyl,
 10 aryl, arylalkyl, heterocycle, or heterocyclealkyl, or wherein R_a and R_b taken together with
 the nitrogen atom to which they are attached form a heterocycle.

- "Haloalkyl" means alkyl, wherein alkyl is defined as above, having one or more
 hydrogen atoms replaced with halogen, wherein halogen is as defined above, including -
 CF₃, -CHF₂, -CH₂F, -CBr₃, -CHBr₂, -CH₂Br, -CCl₃, -CHCl₂, -CH₂Cl, -Cl₃, -CHI₂, -CH₂I,
 15 -CH₂-CF₃, -CH₂-CHF₂, -CH₂-CH₂F, -CH₂-CBr₃, -CH₂-CHBr₂, -CH₂-CH₂Br, -CH₂-CCl₃,
 -CH₂-CHCl₂, -CH₂-CH₂Cl, -CH₂-Cl₃, -CH₂-CHI₂, -CH₂-CH₂I, and the like.

- "Hydroxyalkyl" means alkyl, wherein alkyl is as defined above, having one or
 more hydrogen atoms replaced with hydroxy, including -CH₂OH, -CH₂CH₂OH,
 -(CH₂)₂CH₂OH, -(CH₂)₃CH₂OH, -(CH₂)₄CH₂OH, -(CH₂)₅CH₂OH, -CH(OH)-CH₃,
 20 -CH₂CH(OH)CH₃, and the like.

"Hydroxy" means -OH.

"Sulfonyl" means -SO₃H.

- "Sulfonylalkyl" means -SO₂-(alkyl), wherein alkyl is defined above, including
 -SO₂-CH₃, -SO₂-CH₂CH₃, -SO₂-(CH₂)₂CH₃, -SO₂-(CH₂)₃CH₃, -SO₂-(CH₂)₄CH₃, -SO₂-
 25 (CH₂)₅CH₃, and the like.

"Sulfinylalkyl" means -SO-(alkyl), wherein alkyl is defined above, including
 -SO-CH₃, -SO-CH₂CH₃, -SO-(CH₂)₂CH₃, -SO-(CH₂)₃CH₃, -SO-(CH₂)₄CH₃, -SO-
 (CH₂)₅CH₃, and the like.

- "Sulfonamidoalkyl" means -NHSO₂-(alkyl), wherein alkyl is defined above,
 30 including -NHSO₂-CH₃, -NHSO₂-CH₂CH₃, -NHSO₂-(CH₂)₂CH₃, -NHSO₂-(CH₂)₃CH₃,
 -NHSO₂-(CH₂)₄CH₃, -NHSO₂-(CH₂)₅CH₃, and the like.

"Thioalkyl" means -S-(alkyl), wherein alkyl is defined above, including -S-CH₃,
 -S-CH₂CH₃, -S-(CH₂)₂CH₃, -S-(CH₂)₃CH₃, -S-(CH₂)₄CH₃, -S-(CH₂)₅CH₃, and the like.

- As used herein, the term "JNK Inhibitor" means a compound capable of
 35 inhibiting the activity of JNK *in vitro* or *in vivo*. The JNK Inhibitor can be in the form of

5 a pharmaceutically acceptable salt, free base, solvate, hydrate, stereoisomer, clathrate or prodrug thereof. Such inhibitory activity can be determined by an assay or animal model well-known in the art including those set forth in Section 5. In one embodiment, the JNK Inhibitor is a compound of structure (I)-(III).

“JNK” means a protein or an isoform thereof expressed by a JNK 1, JNK 2, or
10 JNK 3 gene (Gupta, S., Barrett, T., Whitmarsh, A.J., Cavanagh, J., Sluss, H.K., Derijard, B. and Davis, R.J. *The EMBO J.* 15:2760-2770 (1996)).

As used herein, the terms “asbestos-related disease, disorder or syndrome,” “disease or disorder associated with asbestos exposure,” and “disease or disorder associated with asbestos poisoning” mean any disease, disorder, syndrome or
15 abnormality associated with, or related to, exposure to asbestos or poisoning by asbestos. The terms encompass benign and malignant diseases or disorders, and include, but are not limited to, mesothelioma, fibrosis, asbestosis, malignant pleural effusion, benign exudative effusion, pleural plaques, pleural calcification, diffuse pleural thickening, rounded atelectasis, fibrotic masses, and lung cancer. In a specific embodiment, the
20 terms do not encompass lung cancer and in another embodiment do not include fibrosis.

As used herein, the phrase “an effective amount” when used in connection with a JNK Inhibitor means an amount of the JNK Inhibitor that is useful for treating, preventing, and/or managing an asbestos-related disease or disorder.

As used herein, the phrase “an effective amount” when used in connection with
25 another active agent means an amount of the other active agent that is useful for treating, preventing, and/or managing an asbestos-related disease or disorder when administered while the JNK Inhibitor exerts its therapeutic or prophylactic activity.

As used herein, the term “pharmaceutically acceptable salt(s)” refers to a salt prepared from a pharmaceutically acceptable non-toxic acid or base including an
30 inorganic acid and base and an organic acid and base. Suitable pharmaceutically acceptable base addition salts of the JNK Inhibitor include, but are not limited to metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
35 Suitable non-toxic acids include, but are not limited to, inorganic and organic acids such

5 as acetic, alginic, anthranilic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, formic, fumaric, furoic, galacturonic, gluconic, glucuronic, glutamic, glycolic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phenylacetic, phosphoric, propionic, salicylic, stearic, succinic, sulfanilic, sulfuric, tartaric acid, and p-
10 toluenesulfonic acid. Specific non-toxic acids include hydrochloric, hydrobromic, phosphoric, sulfuric, and methanesulfonic acids. Examples of specific salts thus include hydrochloride and mesylate salts. Others are well-known in the art, see for example, *Remington's Pharmaceutical Sciences*, 18th eds., Mack Publishing, Easton PA (1990) or *Remington: The Science and Practice of Pharmacy*, 19th eds., Mack Publishing, Easton
15 PA (1995).

As used herein and unless otherwise indicated, the term "clathrate" means a JNK Inhibitor, or a salt thereof, in the form of a crystal lattice that contains spaces (*e.g.*, channels) that have a guest molecule (*e.g.*, a solvent or water) trapped within.

As used herein and unless otherwise indicated, the term "hydrate" means a JNK
20 Inhibitor, or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.

As used herein and unless otherwise indicated, the term "polymorph" means a particular crystalline arrangement of the JNK Inhibitor. Polymorphs can be obtained through the use of different work-up conditions and/or solvents. In particular,
25 polymorphs can be prepared by recrystallization of a JNK Inhibitor in a particular solvent.

As used herein and unless otherwise indicated, the term "prodrug" means a JNK Inhibitor derivative that can hydrolyze, oxidize, or otherwise react under biological conditions (*in vitro* or *in vivo*) to provide an active compound, particularly a JNK
30 Inhibitor. Examples of prodrugs include, but are not limited to, derivatives and metabolites of a JNK Inhibitor that include biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues. Preferably, prodrugs of compounds with carboxyl functional groups are the
35 lower alkyl esters of the carboxylic acid. The carboxylate esters are conveniently formed

5 by esterifying any of the carboxylic acid moieties present on the molecule. Prodrugs can typically be prepared using well-known methods, such as those described by *Burger's Medicinal Chemistry and Drug Discovery* 6th ed. (Donald J. Abraham *ed.*, 2001, Wiley) and *Design and Application of Prodrugs* (H. Bundgaard *ed.*, 1985, Harwood Academic Publishers Gmhf).

10 As used herein and unless otherwise indicated, the term "stereoisomer" or "stereomerically pure" means one stereoisomer of a compound is substantially free of other stereoisomers of that compound. For example, a stereomerically pure compound having one chiral center will be substantially free of the opposite enantiomer of the compound. A stereomerically pure a compound having two chiral centers will be
15 substantially free of other diastereomers of the compound. A typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, more preferably greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, even
20 more preferably greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomers of the compound, and most preferably greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound.

4. DETAILED DESCRIPTION OF THE INVENTION

25 A first embodiment of the invention encompasses methods of treating, preventing and/or managing an asbestos-related disease or disorder, which comprises administering to a patient in need thereof an effective amount of a JNK Inhibitor.

Another embodiment of the invention encompasses a pharmaceutical composition suitable for treatment, prevention and/or management of asbestos-related
30 diseases or disorders comprising an effective amount of a JNK Inhibitor.

Also encompassed by the invention are single unit dosage forms suitable for use in treating, preventing and/or managing asbestos-related diseases or disorders comprising an effective amount of a JNK Inhibitor, and an optional vehicle, carrier or excipient.

5 Another embodiment of the invention encompasses a kit suitable for use in treating, preventing and/or managing asbestos-related diseases or disorders comprising: a pharmaceutical composition comprising an effective amount of a JNK Inhibitor. The invention further encompasses kits comprising single unit dosage forms.

10 Without being limited by theory, it is believed that a JNK Inhibitor can act in complementary or synergistic ways with certain second active agents in the treatment, prevention and/or management of asbestos-related diseases or disorders. Therefore, one embodiment of the invention encompasses a method of treating, preventing and/or managing an asbestos-related disease or disorder, which comprises administering to a patient in need thereof an effective amount of a JNK Inhibitor, and an effective amount
15 of a second active agent.

 Examples of second active agents include, but are not limited to, conventional therapeutics used to treat or prevent mesothelioma such as anti-cancer agents, antibiotics, anti-inflammatory agents, steroids, cytokines, immunomodulatory agents, immunosuppressive agents, and other therapeutics drug capable of relieving or
20 alleviating a symptom of asbestos-related diseases or disorders which can be found, for example, in the *Physician's Desk Reference*, 2003.

 It is further believed that a JNK Inhibitor can reduce or eliminate adverse effects associated with the administration of conventional therapeutic agents used to treat asbestos-related diseases or disorders, thereby allowing the administration of larger
25 amounts of those conventional agents to patients and/or increasing patient compliance. Consequently, another embodiment of the invention encompasses a method of reversing, reducing or avoiding an adverse effect associated with the administration of a second active agent in a patient suffering from an asbestos-related disease or disorder, which comprises administering to a patient in need thereof an effective amount of a JNK
30 Inhibitor.

 The invention also encompasses pharmaceutical compositions, single unit dosage forms, and kits which comprise an effective amount of a JNK Inhibitor and an effective amount of a second active agent.


 As discussed elsewhere herein, symptoms of asbestos-related diseases or
35 disorders may be treated with chemotherapy, surgery, radiation therapy, photodynamic

5 therapy, immunotherapy, and/or gene therapy. Without being limited by theory, it is believed that the combined use of such conventional therapies and a JNK Inhibitor can provide a uniquely effective treatment of asbestos-related diseases or disorders. Therefore, this invention encompasses a method of treating, preventing and/or managing asbestos-related diseases or disorders, which comprises administering to a patient (*e.g.*, a
 10 human) an effective amount of a JNK Inhibitor, before, during, or after chemotherapy, surgery, radiation therapy, photodynamic therapy, immunotherapy, gene therapy and/or other conventional, non-drug based therapies.

4.1 ILLUSTRATIVE JNK INHIBITORS

As mentioned above, the present invention is directed to methods useful for
 15 treating, preventing and/or managing asbestos-related diseases or disorders, comprising administering an effective amount of a JNK Inhibitor to a patient in need thereof. Illustrative JNK Inhibitors are set forth below.

In one embodiment, the JNK Inhibitor has the following structure (I):



20 wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3 ;

R_2 is $-R_3$, $-R_4$, $-(CH_2)_bC(=O)R_5$, $-(CH_2)_bC(=O)OR_5$, $-(CH_2)_bC(=O)NR_5R_6$,
 25 $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$, $-(CH_2)_bNR_5C(=O)R_6$,
 $-(CH_2)_bNR_5C(=O)NR_6R_7$, $-(CH_2)_bNR_5R_6$, $-(CH_2)_bOR_5$,
 $-(CH_2)_bSO_dR_5$ or $-(CH_2)_bSO_2NR_5R_6$;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected
 30 from 0, 1, 2, 3 or 4;

d is at each occurrence 0, 1 or 2;

5 R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, $-C(=O)OR_8$, $-OC(=O)R_8$, $-C(=O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

10 R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, each being optionally substituted with one to four substituents independently selected from R_3 , or R_4 is halogen or hydroxy;

R_5 , R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, wherein each of R_5 , R_6
15 and R_7 are optionally substituted with one to four substituents independently selected from R_3 ; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocycloalkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein
20 each of R_8 , R_9 , and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3 .

In one embodiment, $-A-R_1$ is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, $-NR_8C(=O)R_9$, $-C(=O)NR_8R_9$, and $-O(CH_2)_bNR_8R_9$, wherein b is 2 or 3 and wherein R_8 and R_9 are defined above.

25 In another embodiment, R_2 is $-R_4$, $-(CH_2)_bC(=O)R_5$, $-(CH_2)_bC(=O)OR_5$, $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$, $-(CH_2)_bNR_5C(=O)R_6$, $-(CH_2)_bNR_5C(=O)NR_6R_7$, $-(CH_2)_bNR_5R_6$, $-(CH_2)_bOR_5$, $-(CH_2)_bSO_dR_5$ or $-(CH_2)_bSO_2NR_5R_6$, and b is an integer ranging from 0-4.

In another embodiment, R_2 is $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bNR_5C(=O)R_6$, 3-
30 triazolyl or 5-tetrazolyl, wherein b is 0 and wherein R_8 and R_9 are defined above.

In another embodiment, R_2 is 3-triazolyl or 5-tetrazolyl.

In another embodiment:

(a) $-A-R_1$ is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, $-NR_8C(=O)R_9$, $-C(=O)NR_8R_9$,
35 and $-O(CH_2)_bNR_8R_9$, wherein b is 2 or 3; and

- 5 (b) R_2 is $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bNR_5C(=O)R_6$, 3-triazolyl or 5-tetrazolyl, wherein b is 0 and wherein R_8 and R_9 are defined above.

In another embodiment:



- (a) $-A-R_1$ is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, $-NR_8C(=O)R_9$, $-C(=O)NR_8R_9$, and $-O(CH_2)_bNR_8R_9$, wherein b is 2 or 3; and
- 10 (b) R_2 is 3-triazolyl or 5-tetrazolyl.

In another embodiment, R_2 is R_4 , and R_4 is 3-triazolyl, optionally substituted at its 5-position with:



- (a) a C_1 - C_4 straight or branched chain alkyl group optionally substituted with a
- 15 hydroxyl, methylamino, dimethylamino or 1-pyrrolidinyl group; or
- (b) a 2-pyrrolidinyl group.

- In another embodiment, R_2 is R_4 , and R_4 is 3-triazolyl, optionally substituted at its 5-position with: methyl, n-propyl, isopropyl, 1-hydroxyethyl, 3-hydroxypropyl, methylaminomethyl, dimethylaminomethyl, 1-(dimethylamino)ethyl, 1-
- 20 pyrrolidinylmethyl or 2-pyrrolidinyl.


In another embodiment, the compounds of structure (I) have structure (IA) when A is a direct bond, or have structure (IB) when A is $-(CH_2)_a-$:




- In other embodiments, the compounds of structure (I) have structure (IC) when A
- 25 is a $-(CH_2)_bCH=CH(CH_2)_c-$, and have structure (ID) when A is $-(CH_2)_bC\equiv C(CH_2)_c-$:



- 5 In further embodiments of this invention, R_1 of structure (I) is aryl or substituted aryl, such as phenyl or substituted phenyl as represented by the following structure (IE):



In another embodiment, R_2 of structure (I) is $-(CH_2)_bNR_4(C=O)R_5$. In one aspect of this embodiment, $b=0$ and the compounds have the following structure (IF):



10


- Representative R_2 groups of the compounds of structure (I) include alkyl (such as methyl and ethyl), halo (such as chloro and fluoro), haloalkyl (such as trifluoromethyl), hydroxy, alkoxy (such as methoxy and ethoxy), amino, arylalkyloxy (such as benzyloxy), mono- or di-alkylamine (such as $-NHCH_3$, $-N(CH_3)_2$ and $-NHCH_2CH_3$),
- 15 $-NHC(=O)R_4$ wherein R_4 is a substituted or unsubstituted phenyl or heteroaryl (such as phenyl or heteroaryl substituted with hydroxy, carboxy, amino, ester, alkoxy, alkyl, aryl, haloalkyl, halo, $-CONH_2$ and $-CONH$ alkyl), $-NH$ (heteroarylalkyl) (such as $-NHCH_2$ (3-pyridyl), $-NHCH_2$ (4-pyridyl), heteroaryl (such as pyrazolo, triazolo and tetrazolo), $-C(=O)NHR_6$ wherein R_6 is hydrogen, alkyl, or as defined above (such as $-C(=O)NH_2$,
- 20 $-C(=O)NHCH_3$, $-C(=O)NH$ (H-carboxyphenyl), $-C(=O)N(CH_3)_2$), arylalkenyl (such as phenylvinyl, 3-nitrophenylvinyl, 4-carboxyphenylvinyl), heteroarylalkenyl (such as 2-pyridylvinyl, 4-pyridylvinyl).

- Representative R_3 groups of the compounds of structure (I) include halogen (such as chloro and fluoro), alkyl (such as methyl, ethyl and isopropyl), haloalkyl (such as trifluoromethyl), hydroxy, alkoxy (such as methoxy, ethoxy, n-propyloxy and isobutyloxy), amino, mono- or di-alkylamino (such as dimethylamine), aryl (such as
- 25


5 phenyl), carboxy, nitro, cyano, sulfinylalkyl (such as methylsulfinyl), sulfonylalkyl (such as methylsulfonyl), sulfonamidoalkyl (such as $\text{-NHSO}_2\text{CH}_3$), $\text{-NR}_8\text{C(=O)(CH}_2)_b\text{OR}_9$ (such as $\text{NHC(=O)CH}_2\text{OCH}_3$), NHC(=O)R_9 (such as -NHC(=O)CH_3 , $\text{-NHC(=O)CH}_2\text{C}_6\text{H}_5$, $\text{-NHC(=O)(2-furanyl)}$), and $\text{-O(CH}_2)_b\text{NR}_8\text{R}_9$ (such as $\text{-O(CH}_2)_2\text{N(CH}_3)_2$).

10 The compounds of structure (I) can be made using organic synthesis techniques known to those skilled in the art, as well as by the methods described in International Publication No. WO 02/10137 (particularly in Examples 1-430, at page 35, line 1 to page 396, line 12), published February 7, 2002, which is incorporated herein by reference in its entirety. Further, specific examples of these compounds are found in this publication.


15 Illustrative examples of JNK Inhibitors of structure (I) are:



3-(4-Fluoro-phenyl)-5-(1H-[1,2,4]triazol-3-yl)-1H-indazole;




3-[3-(2-Piperidin-1-yl-ethoxy)-phenyl]-5-(1H-[1,2,4]triazol-3-yl)-1H-indazole ;




3-(4-Fluoro-phenyl)-1H-indazole-5-carboxylic acid (3-morpholin-4-yl-propyl)-amide ;


5




3-[3-(3-Piperidin-1-yl-propionylamino)-phenyl]-1*H*-indazole-5-carboxylic acid amide ;




3-Benzo[1,3]dioxol-5-yl-5-(2*H*-tetrazol-5-yl)-1*H*-indazole ;



3-(4-Fluoro-phenyl)-5-(5-methyl-[1,3,4]oxadiazol-2-yl)-1*H*-indazole ;




N-tert-Butyl-3-[5-(1*H*-[1,2,4]triazol-3-yl)-1*H*-indazol-3-yl]-benzamide ;




3-[3-(2-Morpholin-4-yl-ethoxy)-phenyl]-5-(1*H*-[1,2,4]triazol-3-yl)-1*H*-indazole ;


5




Dimethyl-(2-{4-[5-(1*H*-[1,2,4]triazol-3-yl)-1*H*-indazol-3-yl]-phenoxy}-ethyl)-amine ;




5-[5-(1,1-Dimethyl-propyl)-1*H*-[1,2,4]triazol-3-yl]-3-(4-fluoro-phenyl)-1*H*-indazole ;



3-(4-Fluoro-phenyl)-5-(5-pyrrolidin-1-ylmethyl-1*H*-[1,2,4]triazol-3-yl)-1*H*-indazole ;



3-(6-Methoxy-naphthalen-2-yl)-5-(5-pyrrolidin-1-ylmethyl-1*H*-[1,2,4]triazol-3-yl)-1*H*-indazole ;




3-(4-Fluoro-phenyl)-1H-indazole-5-carboxylic acid
amide ;

5

and pharmaceutically acceptable salts thereof.

In another embodiment, the JNK Inhibitor has the following structure (II):



(II)

wherein:

10 R_1 is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R_7 ;

R_2 is hydrogen;

R_3 is hydrogen or lower alkyl;

15 R_4 represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl and lower alkoxy;

R_5 and R_6 are the same or different and independently $-R_8$, $-(CH_2)_aC(=O)R_9$, $-(CH_2)_aC(=O)OR_9$, $-(CH_2)_aC(=O)NR_9R_{10}$, $-(CH_2)_aC(=O)NR_9(CH_2)_bC(=O)R_{10}$, $-(CH_2)_aNR_9C(=O)R_{10}$, $(CH_2)_aNR_{11}C(=O)NR_9R_{10}$, $-(CH_2)_aNR_9R_{10}$, $-(CH_2)_aOR_9$, $-(CH_2)_aSO_2R_9$ or $-(CH_2)_aSO_2NR_9R_{10}$;

20

or R_5 and R_6 taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;

R_7 is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, 25 aryl, arylalkyl, heterocycle, substituted heterocycle, heterocycloalkyl, $-C(=O)OR_8$, -

- 5 OC(=O)R₈, -C(=O)NR₈R₉, -C(=O)NR₈OR₉, -SO_cR₈, -SO_cNR₈R₉, -NR₈SO_cR₉, -NR₈R₉, -NR₈C(=O)R₉, -NR₈C(=O)(CH₂)_bOR₉, -NR₈C(=O)(CH₂)_bR₉, -O(CH₂)_bNR₈R₉, or heterocycle fused to phenyl;

R₈, R₉, R₁₀ and R₁₁ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl;

- 10 or R₈ and R₉ taken together with the atom or atoms to which they are attached to form a heterocycle;

a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and

c is at each occurrence 0, 1 or 2.

- 15 In one embodiment, R₁ is a substituted or unsubstituted aryl or heteroaryl. When R₁ is substituted, it is substituted with one or more substituents defined below. In one embodiment, when substituted, R₁ is substituted with a halogen, -SO₂R₈ or -SO₂R₈R₉.

- In another embodiment, R₁ is substituted or unsubstituted aryl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl or quinazolinyl.

- In another embodiment R₁ is substituted or unsubstituted aryl or heteroaryl. When R₁ is substituted, it is substituted with one or more substituents defined below. In one embodiment, when substituted, R₁ is substituted with a halogen, -SO₂R₈ or -SO₂R₈R₉.


- In another embodiment, R₁ is substituted or unsubstituted aryl, preferably phenyl. When R₁ is a substituted aryl, the substituents are defined below. In one embodiment, when substituted, R₁ is substituted with a halogen, -SO₂R₈ or -SO₂R₈R₉.

- 30 In another embodiment, R₅ and R₆, taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted nitrogen-containing non-aromatic heterocycle, in one embodiment, piperazinyl, piperidinyl or morpholinyl.

- When R₅ and R₆, taken together with the nitrogen atom to which they are attached form substituted piperazinyl, piperadinyl or morpholinyl, the piperazinyl, piperadinyl or morpholinyl is substituted with one or more substituents defined below. In one

- 5 embodiment, when substituted, the substituent is alkyl, amino, alkylamino, alkoxyalkyl, acyl, pyrrolidinyl or piperidinyl.

In one embodiment, R_3 is hydrogen and R_4 is not present, and the JNK Inhibitor has the following structure (IIA):




10

(IIA)

and pharmaceutically acceptable salts thereof.

In a more specific embodiment, R_1 is phenyl optionally substituted with R_7 , and having the following structure (IIB):




15

(IIB)

and pharmaceutically acceptable salts thereof.

In still a further embodiment, R_7 is at the para position of the phenyl group relative to the pyrimidine, as represented by the following structure (IIC):




(IIC)

- 20 and pharmaceutically acceptable salts thereof.


The JNK Inhibitors of structure (II) can be made using organic synthesis techniques known to those skilled in the art, as well as by the methods described in

- 5 International Publication No. WO 02/46170 (particularly Examples 1-27 at page 23, line 5 to page 183, line 25), published June 13, 2002, which is hereby incorporated by reference in its entirety. Further, specific examples of these compounds are found in the publication.


Illustrative examples of JNK Inhibitors of structure (II) are:



10 4-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-benzamide ;




4-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-N,N-dimethylbenzamide ;




4-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-N-(3-piperidin-1-yl-propyl)-benzamide ;


5




{4-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-phenyl}-
piperazin-1-yl-methanone ;



1-(4-{4-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-benzoyl}-
piperazin-1-yl)-ethanone ;




1-[4-(4-{4-[4-(3-Hydroxy-propylsulfanyl)-phenyl]-pyrimidin-2-ylamino}-benzoyl)-
piperazin-1-yl]-ethanone ;



{4-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-phenyl}-(4-pyrrolidin-1-yl)-
piperidin-1-yl-methanone ;

and pharmaceutically acceptable salts thereof.

5 In another embodiment, the JNK Inhibitor has the following structure (III):




(III)

wherein R_0 is -O-, -S-, -S(O)-, -S(O)₂-, NH or -CH₂-;

the compound of structure (III) being: (i) unsubstituted, (ii) monosubstituted and having a first substituent, or (iii) disubstituted and having a first substituent and a second substituent;


the first or second substituent, when present, is at the 3, 4, 5, 7, 8, 9, or 10 position, wherein the first and second substituent, when present, are independently alkyl, hydroxy, halogen, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by structure (a), (b), (c), (d), (e), or (f):



5 wherein R₃ and R₄ are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R₃ and R₄ are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and

R₅ is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, 10 alkoxyalkyl, alkoxycarbonylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl.

In another embodiment, the JNK Inhibitor has the following structure (IIIA):




15 *2H-Dibenzo[cd,g]indol-6-one*
(IIIA)

being: (i) unsubstituted, (ii) monosubstituted and having a first substituent, or (iii) disubstituted and having a first substituent and a second substituent;

the first or second substituent, when present, is at the 3, 4, 5, 7, 8, 9, or 10 position;

20 wherein the first and second substituent, when present, are independently alkyl, hydroxy, halogen, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by structure (a), (b), (c), (d), (e), or (f):



5

wherein R_3 and R_4 are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R_3 and R_4 are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and

10 R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxy carbonylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl.

15 A subclass of the compounds of structure (IIIA) is that wherein the first or second substituent is present at the 5, 7, or 9 position. In one embodiment, the first or second substituent is present at the 5 or 7 position.


A second subclass of compounds of structure (IIIA) is that wherein the first or second substituent is present at the 5, 7, or 9 position;

20 the first or second substituent is independently alkoxy, aryloxy, aminoalkyl, mono-alkylaminoalkyl, di-alkylaminoalkyl, or a group represented by the structure (a), (c), (d), (e), or (f);

R_3 and R_4 are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or cycloalkylalkyl; and

R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or cycloalkylalkyl.

25 In another embodiment, the JNK Inhibitor has the following structure (IIIB):




2-Oxo-2H-21⁴-anthra[9,1-cd]
isothiazol-6-one
(IIIB)

5

being (i) unsubstituted, (ii) monosubstituted and having a first substituent, or (ii) disubstituted and having a first substituent and a second substituent;

the first or second substituent, when present, is at the 3, 4, 5, 7, 8, 9, or 10 position;

10 wherein the first and second substituent, when present, are independently alkyl, halogen, hydroxy, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxy, alkoxyalkyl, alkoxyalkoxy, aryl, aryloxy, arylalkoxy, arylalkyl, cycloalkylalkoxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by structure (a), (b) (c), (d), (e), or (f):



15

wherein R₃ and R₄ are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R₃ and R₄ are independently hydrogen, alkyl, cycloalkyl,

5 aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and

R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxycarbonylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-
10 alkylaminoalkyl, or di-alkylaminoalkyl.


A subclass of the compounds of structure (IIIB) is that wherein the first or second substituent is present at the 5, 7, or 9 position. In one embodiment, the first or second substituent is present at the 5 or 7 position.

A second subclass of the compounds of structure (IIIB) is that wherein the first or
15 second substituent is independently alkoxy, aryloxy, or a group represented by the structure (a), (c), (d), (e), or (f);

R_3 and R_4 are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or cycloalkylalkyl; and

R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or cycloalkylalkyl.

20 In another embodiment, the JNK Inhibitor has the following structure (IIIC):




2-Oxa-1-aza-aceanthrylen-6-one
(IIIC)

being (i) monosubstituted and having a first substituent or (ii) disubstituted and having a first substituent and a second substituent;

the first or second substituent, when present, is at the 3, 4, 5, 7, 8, 9, or 10
25 position;

wherein the first and second substituent, when present, are independently alkyl, halogen, hydroxy, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl,

- 5 alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by structure (a), (b), (c) (d), (e), or (f):



- wherein R_3 and R_4 are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R_3 and R_4 are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and

- R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxyalkylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl.


A subclass of the compounds of structure (IIIC) is that wherein the first or second substituent is present at the 5, 7, or 9 position. In one embodiment, the first or second substituent is present at the 5 or 7 position.

- 20 A second subclass of the compounds of structure (IIIC) is that wherein the first or second substituent is independently alkoxy, aryloxy, aminoalkyl, mono-alkylaminoalkyl, di-alkylaminoalkyl, or a group represented by the structure (a), (c), (d), (e), or (f);

R_3 and R_4 are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or cycloalkylalkyl; and

- 25 R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or cycloalkylalkyl.


5 In another embodiment, the JNK Inhibitor has the following structure (IIID):



2,2-Dioxo-2H-21⁶-anthra
[9,1-cd]isothiazol-6-one
(IIID)

being (i) monosubstituted and having a first substituent present at the 5, 7, or 9 position, (ii) disubstituted and having a first substituent present at the 5 position and a second substituent present at the 7 position, (iii) disubstituted and having a first substituent present at the 5 position and a second substituent present at the 9 position, or
10 (iv) disubstituted and having a first substituent present at the 7 position and a second substituent present at the 9 position;

wherein the first and second substituent, when present, are independently alkyl, halogen, hydroxy, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl,
15 alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by structure (a), (b), (c), (d), (e), or (f):



5 wherein R₃ and R₄ are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R₃ and R₄ are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and

R₅ is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, 10 alkoxyalkyl, alkoxycarbonylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl.

A subclass of the compounds of structure (IIID) is that wherein the first or second substituent is present at the 5 or 7 position.


15 A second subclass of the compounds of structure (IIID) is that wherein the first or second substituent is independently alkyl, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by structure (a), (c), (d), (e), or (f).

20 Another subclass of the compounds of structure (IIID) is that wherein the first and second substituent are independently alkoxy, aryloxy, or a group represented by the structure (a), (c), (d), (e), or (f);

R₃ and R₄ are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or cycloalkylalkyl; and

25 R₅ is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, alkoxycarbonyl, or cycloalkylalkyl.


In another embodiment, the JNK Inhibitor has the following structure (IIIE):



Anthra[9,1-cd]isothiazol-6-one
(IIIE)

- 5 being (i) monosubstituted and having a first substituent present at the 5, 7, or 9 position, (ii) disubstituted and having a first substituent present at the 5 position and a second substituent present at the 9 position, (iii) disubstituted and having a first substituent present at the 7 position and a second substituent present at the 9 position, or
 10 (iv) disubstituted and having a first substituent present at the 5 position and a second substituent present at the 7 position;

wherein the first and second substituent, when present, are independently alkyl, halogen, hydroxy, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group
 15 represented by structure (a), (b), (c), (d), (e), or (f):



wherein R_3 and R_4 are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R_3 and R_4 are independently hydrogen, alkyl, cycloalkyl,
 20 aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and


R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxycarbonylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-
 25 alkylaminoalkyl, or di-alkylaminoalkyl.

5 A subclass of the compounds of structure (IIIE) is that wherein the first or second substituent is present at the 5 or 7 position.

A second subclass of the compounds of structure (IIIE) is that wherein the compound of structure (IIIE) is disubstituted and at least one of the substituents is a group represented by the structure (d) or (f).

10 Another subclass of the compounds of structure (IIIE) is that wherein the compounds are monosubstituted. Yet another subclass of compounds is that wherein the compounds are monosubstituted at the 5 or 7 position with a group represented by the structure (e) or (f).

In another embodiment, the JNK Inhibitor has the following structure (IIIF):




2H-Dibenzo[cd,g]indazol-6-one
(IIIF)

15

being (i) unsubstituted, (ii) monosubstituted and having a first substituent, or (iii) disubstituted and having a first substituent and a second substituent;

the first or second substituent, when present, is at the 3, 4, 5, 7, 8, 9, or 10 position;

20 wherein the first and second substituent, when present, are independently alkyl, hydroxy, halogen, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono- alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by structure (a), (b), (c), (d), (e), or (f):



5


wherein R_3 and R_4 are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R_3 and R_4 are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and

10 R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxy carbonylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl.

15 In one embodiment, the compound of structure (IIIF), or a pharmaceutically acceptable salt thereof is unsubstituted at the 3, 4, 5, 7, 8, 9, or 10 position.


The JNK Inhibitors of structure (III) can be made using organic synthesis techniques known to those skilled in the art, as well as by the methods described in International Publication No. WO 01/12609 (particularly Examples 1-7 at page 24, line 6 to page 49, line 16), published February 22, 2001, as well as International Publication
20 No. WO 02/066450 (particularly compounds AA-HG at pages 59-108), published August 29, 2002, each of which is hereby incorporated by reference in its entirety. Further, specific examples of these compounds can be found in the publications.

Illustrative examples of JNK Inhibitors of structure (III) are:




2*H*-Dibenzo[*cd,g*]
indazol-6-one ;


5




7-Chloro-2*H*-dibenzo[*cd,g*]
indazol-6-one ;



5-Dimethylamino-2*H*-
dibenzo[*cd,g*]indazol-6-one;




7-Benzoyloxy-2*H*-dibenzo[*cd,g*]indazol-
6-one ;




N-(6-Oxo-2,6-dihydro-
dibenzo[*cd,g*]indazol-5-yl)-
acetamide ;


5




5-(2-Piperidin-1-yl-ethylamino)-2*H*-
dibenzo[*cd,g*]indazol-6-one ;




5-Amino-anthra[9,1-
cd]isothiazol-6-one ;



N-(6-Oxo-6*H*-anthra[9,1-*cd*]isothiazol-5-
yl)-benzamide ;



7-Dimethylamino-anthra[9,1-cd]isothiazol-6-one ;



2-Oxa-1-aza-aceanthrylen-6-one;

and pharmaceutically acceptable salts thereof.

Other JNK Inhibitors that are useful in the present methods include, but are not limited to, those disclosed in International Publication No. WO 00/39101, (particularly at page 2, line 10 to page 6, line 12); International Publication No. WO 01/14375 (particularly at page 2, line 4 to page 4, line 4); International Publication No. WO 00/56738 (particularly at page 3, line 25 to page 6, line 13); International Publication No. WO 01/27089 (particularly at page 3, line 7 to page 5, line 29); International Publication No. WO 00/12468 (particularly at page 2, line 10 to page 4, line 14); European Patent Publication 1 110 957 (particularly at page 19, line 52 to page 21, line 9); International Publication No. WO 00/75118 (particularly at page 8, line 10 to page 11, line 26); International Publication No. WO 01/12621 (particularly at page 8, line 10 to page 10, line 7); International Publication No. WO 00/64872 (particularly at page 9, line 1 to page, 106, line 2); International Publication No. WO 01/23378 (particularly at page 90, line 1 to page 91, line 11); International Publication No. WO 02/16359 (particularly at page 163, line 1 to page 164, line 25); United States Patent No. 6,288,089 (particularly at column 22, line 25 to column 25, line 35); United States Patent No. 6,307,056 (particularly at column 63, line 29 to column 66, line 12); International Publication No. WO 00/35921 (particularly at page 23, line 5 to page 26, line 14); International

5 Publication No. WO 01/91749 (particularly at page 29, lines 1-22); International
Publication No. WO 01/56993 (particularly in at page 43 to page 45); and International
Publication No. WO 01/58448 (particularly in at page 39), each of which is incorporated
by reference herein in its entirety.

10 Pharmaceutical compositions including dosage forms of the invention, which
comprise an effective amount of a JNK Inhibitor can be used in the methods of the
invention.

4.2 METHODS OF USE

Methods of this invention encompass methods of treating, preventing and/or
managing various types of asbestos-related diseases or disorders. As used herein, unless
15 otherwise specified, the term "treating" refers to the administration of an effective
amount of a JNK Inhibitor after the onset of symptoms of asbestos-related diseases or
disorders, whereas "preventing" refers to the administration prior to the onset of
symptoms, particularly to patients at risk of mesothelioma or other asbestos-related
disorders. The term "preventing" further includes the inhibiting or averting a symptom
20 of the particular disease or disorder. Symptoms of asbestos-related diseases or disorders
include, but are not limited to, dyspnea, obliteration of the diaphragm, radiolucent sheet-
like encasement of the pleura, pleural effusion, pleural thickening, decreased size of the
chest, chest discomfort, chest pain, easy fatigability, fever, sweats and weight loss.
Examples of patients at risk of asbestos-related diseases or disorders include, but are not
25 limited to, those who have been exposed to asbestos in the workplace and their family
members who have been exposed to asbestos embedded in the worker's clothing.
Patients having familial history of asbestos-related diseases or disorders are also
preferred candidates for preventive regimens.

As used herein and unless otherwise indicated, the term "managing asbestos-
30 related diseases or disorders" encompasses preventing the recurrence of the diseases or
disorders in a patient who had suffered from the diseases or disorders, and/or lengthening
the time that a patient who had suffered from those remains in remission.

In one embodiment, methods encompassed by this invention comprise
administering an effective amount of a JNK Inhibitor to a patient (*e.g.*, a human)
35 suffering, or likely to suffer, from asbestos-related diseases or disorders.

5 Without being limited by theory, it is believed that a JNK Inhibitor can be prophylactically administered to prevent people who have been previously exposed to asbestos from developing asbestos-related diseases or disorders. This prophylactic method can actually prevent asbestos-related diseases or disorders from developing in the first place. Therefore, the invention further encompasses a method for preventing
10 asbestos-related diseases or disorders in people who are at risk of asbestos-related diseases or disorders, comprising administering an effective amount of a JNK Inhibitor to a patient in need thereof.

 Without being limited by theory, it is also believed that a JNK Inhibitor can inhibit spread of asbestos-related diseases or disorders after diagnosis, because the
15 compounds can affect the production of cytokines (*e.g.*, TNF- α).

 The invention encompasses methods for treating, preventing and/or managing asbestos-related diseases or disorders in patients with various stages and specific types of the diseases, including, but not limited to, malignant mesothelioma, asbestosis, malignant pleural effusion, benign pleural effusion, pleural plaque, pleural calcification, diffuse
20 pleural thickening, round atelectasis, and bronchogenic carcinoma. It further encompasses methods of treating patients who have been previously treated for asbestos-related diseases or disorders but were not sufficiently responsive or were non-responsive, as well as those who have not previously been treated for the diseases or disorders. Because patients have heterogenous clinical manifestations and varying clinical
25 outcomes, the treatment given to a patient may vary, depending on his/her prognosis. The skilled clinician will be able to readily determine without undue experimentation specific secondary agents and types of physical therapy that can be effectively used to treat an individual patient.

 In one embodiment of the invention, a JNK Inhibitor is administered
30 orally and daily in an amount of from about 1 mg to about 10,000 mg. More specifically, the daily dose is administered twice daily in equally divided doses. Specifically, a daily dose range can be from about 1 mg to about 5,000 mg per day, from about 10 mg to about 2,500 mg per day, from about 100 mg to about 800 mg per day, from about 100 mg to about 1,200 mg per day, or from about 25 mg to about 2,500 mg
35 per day. In managing the patient, the therapy should be initiated at a lower dose, perhaps

- 5 about 1 mg to about 2,500 mg, and increased if necessary up to about 200 mg to about 5,000 mg per day as either a single dose or divided doses, depending on the patient's global response.

4.2.1 Combination Therapy With A Second Active Agent

- The invention further relates to methods for treating, preventing and/or managing
10 an asbestos-related disease or disorder, comprising administering an effective amount of a JNK Inhibitor in combination with an effective amount of a second active agent, such as a prophylactic or therapeutic agent, to a patient in need thereof.

- It is believed that certain combinations work synergistically in the treatment of asbestos-related diseases or disorders. A JNK Inhibitor can also work to alleviate
15 adverse effects associated with certain second active agents, and some second active agents can be used to alleviate adverse effects associated with a JNK Inhibitor.

- One or more second active agents can be used in the methods and compositions of the invention together with a JNK Inhibitor. Second active agents can be large molecules (*e.g.*, proteins) or small molecules (*e.g.*, synthetic inorganic, organometallic,
20 or organic molecules).

- Examples of large molecule active agents are biological molecules, such as naturally occurring or artificially made proteins. Particular proteins include, but are not limited to: cytokines such as GM-CSF, interleukins such as IL-2 (including recombinant IL-II ("rIL2") and canarypox IL-2), IL-10, IL-12, and IL-18; and interferons, such as
25 interferon alfa-2a, interferon alfa-2b, interferon alfa-n1, interferon alfa-n3, interferon beta-1a, and interferon gamma-1b.

- In one embodiment of the invention, the large molecule active agent reduces, eliminates, or prevents an adverse effect associated with the administration of a JNK Inhibitor. Depending on the disease or disorder being treated, adverse effects can
30 include, but are not limited to, drowsiness, somnolence, nausea, emesis, gastrointestinal discomfort, diarrhea, and vasculitis.

- Second active agents that are small molecules can also be used to alleviate adverse effects associated with the administration of a JNK Inhibitor. Like some large molecules, many are believed to be capable of providing a synergistic effect when
35 administered with (*e.g.*, before, after or simultaneously) a JNK Inhibitor. Examples of

5 small molecule second active agents include, but are not limited to, anti-cancer agents, antibiotics, anti-inflammatory agents, IMiDs[®] and SelCIDs[®] (Celgene Corporation, New Jersey) (*e.g.*, those disclosed in U.S. patent nos. 6,075,041; 5,877,200; 5,698,579; 5,703,098; 6,429,221; 5,736,570; 5,658,940; 5,728,845; 5,728,844; 6,262,101; 6,020,358; 5,929,117; 6,326,388; 6,281,230; 5,635,517; 5,798,368; 6,395,754; 10 5,955,476; 6,403,613; 6,380,239; and 6,458,810, each of which is incorporated herein by reference) and steroids.

Examples of anti-cancer agents include, but are not limited to: acivicin; aclarubicin; acodazole hydrochloride; acronine; 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione (Actimid[™]); adozelesin; aldesleukin; altretamine; ambomycin; 15 ametantrone acetate; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; broprimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; celecoxib (COX-2 20 inhibitor); chlorambucil; cirolemycin; cisplatin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; 25 elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin 30 hydrochloride; ifosfamide; ilmofofosine; ioproplatin; irinotecan; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocil; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedopa; 35 mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper;

- 5 mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; 3-(4-amino-1-oxo-1,3-dihydro-
- 10 isoindol-2-yl)-piperidine-2,6-dione (Revimid™); riboprine; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spirolatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; taxotere; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa;
- 15 tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triceribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulazole hydrochloride; uracil mustard; uredepa; vaporeotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin;
- 20 zinostatin; and zorubicin hydrochloride.

- Other anti-cancer drugs include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole;
- 25 andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin
- 30 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; broprimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives;
- 35 capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN

- 5 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS);
castanospermine; cecropin B; cetrorelix; chlorlins; chloroquinoxaline sulfonamide;
cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A;
collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin
816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A;
- 10 cyclopentantraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor;
cytostatin; dacliximab; decitabine; dehydroidemnin B; deslorelin; dexamethasone;
dexifosfamide; dexrazoxane; dexverapamil; diaziqune; didemnin B; didox;
diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin; diphenyl
spiromustine; docetaxel; docosanol; dolasetron; doxifluridine; doxorubicin; droloxifene;
- 15 dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab;
eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen
agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole;
fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone;
fludarabine; fluorodaunorubicin hydrochloride; forfenimex; formestane; fostriecin;
- 20 fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase
inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene
bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofofosine;
ilomastat; imatinib (*e.g.*, Gleevec®), imiquimod; immunostimulant peptides; insulin-like
growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins;
- 25 iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole;
isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate;
lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia
inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone;
leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide
- 30 peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine;
lometrexol; lonidamine; losoxantrone; loxoribine; lurtotecan; lutetium texaphyrin;
lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocil; maspin;
matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone;
meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine;
- 35 mirimostim; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin

- 5 fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; Erbitux, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin;
- 10 neridronic acid; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; oblimersen (Genasense[®]); O⁶-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues; paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol;
- 15 panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein
- 20 transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; sizofiran; sobuzoxane; sodium
- 30 borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase
- 35 inhibitors; temoporfin; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine;

5 thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin
 receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin;
 tirapazamine; titanocene bichloride; topsentin; toremifene; translation inhibitors;
 tretinoin; triacetyluridine; tricyribine; trimetrexate; triptorelin; tropisetron; turosteride;
 tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital
 10 sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide;
 variolin B; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin;
 vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.

Specific second active agents include, but are not limited to, anthracycline,
 platinum, alkylating agent, oblimersen (Genasense[®]), gemcitabine, cisplatin,
 15 cyclophosphamide, temodar, carboplatin, procarbazine, gliadel, tamoxifen, methotrexate,
 taxotere, irinotecan, topotecan, temozolomide, capecitabine, cisplatin, thiotepa,
 fludarabine, liposomal daunorubicin, cytarabine, doxorubicin, paclitaxel, vinblastine, IL-2,
 GM-CSF, dacarbazine, vinorelbine, zoledronic acid, palmitronate, biaxin, busulphan,
 prednisone, bisphosphonate, arsenic trioxide, vincristine, doxorubicin (Doxil[®]),
 20 paclitaxel, ganciclovir, adriamycin, bleomycin, hyaluronidase, mepacrine, thiotepa,
 tetracycline, thalidomide and mitomycin C.

In one embodiment, a JNK Inhibitor and a second active agent are administered
 to a patient, preferably a mammal, more preferably a human, in a sequence and within a
 time interval such that the JNK Inhibitor can act together with the other agent to provide
 25 an increased benefit than if they were administered otherwise. For example, the second
 active agent can be administered at the same time or sequentially in any order at different
 points in time; however, if not administered at the same time, they should be
 administered sufficiently close in time so as to provide the desired therapeutic or
 prophylactic effect. In one embodiment, the JNK Inhibitor and the second active agent
 30 exert their effect at times which overlap. Each second active agent can be administered
 separately, in any appropriate form and by any suitable route. In other embodiments, the
 JNK Inhibitor is administered before, concurrently or after administration of the second
 active agent.

In various embodiments, the JNK Inhibitor and the second active agent are
 35 administered less than about 1 hour apart, at about 1 hour apart, at about 1 hour to about

5 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours
apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at
about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8
hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours
to about 11 hours apart, at about 11 hours to about 12 hours apart, no more than 24 hours
10 apart or no more than 48 hours apart. In other embodiments, the JNK Inhibitor and the
second active agent are administered concurrently.

In other embodiments, the JNK Inhibitor and the second active agent are
administered at about 2 to 4 days apart, at about 4 to 6 days apart, at about 1 week part,
at about 1 to 2 weeks apart, or more than 2 weeks apart.

15 In certain embodiments, the JNK Inhibitor and optionally the second active agent
are cyclically administered to a patient. Cycling therapy involves the administration of a
first agent for a period of time, followed by the administration of a second agent and/or
third agent for a period of time and repeating this sequential administration. Cycling
therapy can reduce the development of resistance to one or more of the therapies, avoid
20 or reduce the side effects of one of the therapies, and/or improve the efficacy of the
treatment.

In certain embodiments, the JNK Inhibitor and optionally the second active agent
are administered in a cycle of less than about 3 weeks, about once every two weeks,
about once every 10 days or about once every week. One cycle can comprise the
25 administration of a JNK Inhibitor and optionally the second active agent by infusion over
about 90 minutes every cycle, about 1 hour every cycle, about 45 minutes every cycle.
Each cycle can comprise at least 1 week of rest, at least 2 weeks of rest, at least 3 weeks
of rest. The number of cycles administered is from about 1 to about 12 cycles, more
typically from about 2 to about 10 cycles, and more typically from about 2 to about 8
30 cycles.

In yet other embodiments, the JNK Inhibitor is administered in metronomic
dosing regimens, either by continuous infusion or frequent administration without
extended rest periods. Such metronomic administration can involve dosing at constant
intervals without rest periods. Typically the JNK Inhibitors, are used at lower doses.
35 Such dosing regimens encompass the chronic daily administration of relatively low doses

5 for extended periods of time. In preferred embodiments, the use of lower doses can minimize toxic side effects and eliminate rest periods. In certain embodiments, the JNK Inhibitor is delivered by chronic low-dose or continuous infusion ranging from about 24 hours to about 2 days, to about 1 week, to about 2 weeks, to about 3 weeks to about 1 month to about 2 months, to about 3 months, to about 4 months, to about 5 months, to
10 about 6 months. The scheduling of such dose regimens can be optimized by the skilled artisan.

In other embodiments, courses of treatment are administered concurrently to a patient, *i.e.*, individual doses of the second active agent are administered separately yet within a time interval such that the JNK Inhibitor can work together with the second
15 active agent. For example, one component can be administered once per week in combination with the other components that can be administered once every two weeks or once every three weeks. In other words, the dosing regimens are carried out concurrently even if the therapeutics are not administered simultaneously or during the same day.

20 The second active agent can act additively or, more preferably, synergistically with the JNK Inhibitor. In one embodiment, a JNK Inhibitor is administered concurrently with one or more second active agents in the same pharmaceutical composition. In another embodiment, a JNK Inhibitor is administered concurrently with one or more second active agents in separate pharmaceutical compositions. In still
25 another embodiment, a JNK Inhibitor is administered prior to or subsequent to administration of a second active agent. The invention contemplates administration of a JNK Inhibitor and a second active agent by the same or different routes of administration, *e.g.*, oral and parenteral. In certain embodiments, when a JNK Inhibitor is administered concurrently with a second active agent that potentially produces adverse
30 side effects including, but not limited to, toxicity, the second active agent can advantageously be administered at a dose that falls below the threshold that the adverse side effect is elicited.

4.2.2 Use With Conventional Therapy

The standard methods of chemotherapy, radiation therapy, photodynamic
35 therapy, and surgery are used for treating or managing mesothelioma. Kaiser LR., *Semin*

5 *Thorac Cardiovasc Surg.* Oct;9(4):383-90, 1997. Intracavitary approaches using targeted cytokines and gene therapy have been tried in patients with mesothelioma using intratumoral gene transfer of recombinant adenovirus (rAd) containing herpes simplex virus thymidine kinase (HSVtk) gene into the pleural space of patients. *Id.* and Sterman DH, *Hematol Oncol Clin North Am.* Jun;12(3):553-68, 1998.

10 Certain embodiments of this invention encompass methods of treating or managing asbestos-related diseases or disorders, which comprise administering an effective amount of a JNK Inhibitor in conjunction with (*e.g.*, before, during, or after) conventional therapy including, but not limited to, chemotherapy, surgery, photodynamic therapy, radiation therapy, gene therapy, immunotherapy or other non-drug based
15 therapy presently used to treat or manage the diseases or disorders. The combined use of a JNK Inhibitor and conventional therapy can provide a unique treatment regimen that is unexpectedly effective in certain patients.

 As discussed elsewhere herein, the invention encompasses a method of reducing, treating and/or preventing adverse or undesired effects associated with conventional
20 therapy including, but not limited to, chemotherapy, photodynamic therapy, surgery, radiation therapy, gene therapy, and immunotherapy. A JNK Inhibitor and another active agent can be administered to a patient prior to, during, or after the occurrence of the adverse effect associated with conventional therapy. Examples of adverse effects associated with chemotherapy and radiation therapy that can be treated or prevented by
25 this method include, but are not limited to: gastrointestinal toxicity such as, but not limited to, early and late-forming diarrhea and flatulence; nausea; vomiting; anorexia; leukopenia; anemia; neutropenia; asthenia; abdominal cramping; fever; pain; loss of body weight; dehydration; alopecia; dyspnea; insomnia; dizziness, mucositis, xerostomia, and kidney failure.

30 In one embodiment, a JNK Inhibitor is administered in an amount of from about 1 mg to about 5,000 mg per day, from about 1 mg to about 5,000 mg per day, from about 10 mg to about 2,500 mg per day, from about 100 mg to about 800 mg per day, from about 100 mg to about 1,200 mg per day, or from about 25 mg to about 2,500 mg per day orally and daily alone, or in combination with a second active agent disclosed herein
35 (*see, e.g.*, section 4.2.1), prior to, during, or after the use of conventional therapy. In a

5 specific embodiment of this method, an effective amount of a JNK Inhibitor is administered to a patient with mesothelioma who was previously treated with radiotherapy.

In one embodiment of this method, an effective amount of a JNK Inhibitor is administered to a patient with an asbestos-related disease or disorder in combination with
10 trimodality therapy. Trimodality therapy involves a combination of three standard strategies of surgery, chemotherapy, and radiation therapy. In one embodiment of this method, extrapleural pneumonectomy is followed by a combination of chemotherapy using a JNK Inhibitor and radiotherapy. In another embodiment of the trimodality treatment, a JNK Inhibitor is administered in combination with a different
15 chemotherapeutic regimen including a combination of cyclophosphamide/adriamycin/cisplatin, carboplatin/paclitaxel, or cisplatin/methotrexate/vinblastine.

4.2.3 Cycling Therapy

In certain embodiments, a JNK Inhibitor is cyclically administered to a patient. Cycling therapy involves the administration of a JNK Inhibitor for a period of time,
20 followed by a rest for a period of time, and repeating this sequential administration. Cycling therapy can reduce the development of resistance to one or more of the therapies, avoid or reduce the side effects of one of the therapies, and/or improves the efficacy of the treatment. Consequently, in one specific embodiment of the invention, a JNK Inhibitor is administered daily in a single or divided doses in a four to six week
25 cycle with a rest period of about a week or two weeks. Typically, the number of cycles during which the combinatorial treatment is administered to a patient will be from about one to about 24 cycles, more typically from about two to about 16 cycles, and even more typically from about four to about six cycles. The invention further allows the frequency, number, and length of dosing cycles to be increased. Thus, a specific
30 embodiment of the invention encompasses the administration of a JNK Inhibitor for more cycles than are typical when it is administered alone. In another specific embodiment of the invention, a JNK Inhibitor is administered for a greater number of cycles that would typically cause dose-limiting toxicity in a patient to whom a second active agent is not also being administered.

5 In one embodiment, a JNK Inhibitor is administered daily and continuously for three or four weeks at a dose of from about 400 to about 1,200 mg/d followed by a break of one or two weeks in a four or six week cycle.

 In another embodiment of the invention, a JNK Inhibitor and a second active agent are administered orally, with administration of a JNK Inhibitor occurring 30 to 60
10 minutes prior to a second active agent, during a cycle of four to six weeks.

 In another embodiment, a JNK Inhibitor is administered with cisplatin in an amount of 100 mg/m² on day 1 and gemcitabine in an amount of 1000 mg/m² intravenously on days 1, 8, and day 15 of a 28-day cycle for 6 cycles.

4.3 PHARMACEUTICAL COMPOSITIONS

15 The compositions comprising a JNK Inhibitor include bulk-drug compositions useful in the manufacture of pharmaceutical compositions (*e.g.*, impure or non-sterile compositions) and pharmaceutical compositions (*i.e.*, compositions that are suitable for administration to a patient) which can be used in the preparation of unit dosage forms. Such compositions optionally comprise a prophylactically or therapeutically effective
20 amount of a prophylactic and/or therapeutic agent disclosed herein or a combination of those agents and a pharmaceutically acceptable vehicle, carrier or excipient. Preferably, compositions of the invention comprise a prophylactically or therapeutically effective amount of JNK Inhibitor and a second active agent, and a pharmaceutically acceptable vehicle, carrier or excipient.

25 In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which a JNK Inhibitor is administered. Such pharmaceutical vehicles
30 can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical vehicles can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents can be used. When administered to a patient, the
35 pharmaceutically acceptable vehicles are preferably sterile. Water can be the vehicle

5 when the JNK Inhibitor is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid vehicles, particularly for injectable solutions. Suitable pharmaceutical vehicles also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol,
10 propyleneglycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

The present compositions can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form
15 suitable for use. In one embodiment, the pharmaceutically acceptable vehicle is a capsule (see *e.g.*, U.S. Patent No. 5,698,155). Other examples of suitable pharmaceutical vehicles are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

In a preferred embodiment, the JNK Inhibitor and optionally another therapeutic or prophylactic agent are formulated in accordance with routine procedures as
20 pharmaceutical compositions adapted for intravenous administration to human beings. Typically, JNK Inhibitors for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the compositions can also include a solubilizing agent. Compositions for intravenous administration can optionally include a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the
25 ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the JNK Inhibitor is to be administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where
30 the JNK Inhibitor is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.

Compositions for oral delivery can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs, for example. Orally administered compositions can contain one or more optional agents, for example,
35 sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as

5 peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving
10 compound are also suitable for an orally administered JNK Inhibitor. In these later platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time delay material
15 such as glycerol monostearate or glycerol stearate can also be used. Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. Such vehicles are preferably of pharmaceutical grade.

Further, the effect of the JNK Inhibitor can be delayed or prolonged by proper
20 formulation. For example, a slowly soluble pellet of the JNK Inhibitor can be prepared and incorporated in a tablet or capsule. The technique can be improved by making pellets of several different dissolution rates and filling capsules with a mixture of the pellets. Tablets or capsules can be coated with a film which resists dissolution for a predictable period of time. Even the parenteral preparations can be made long-acting, by dissolving
25 or suspending the compound in oily or emulsified vehicles which allow it to disperse only slowly in the serum.

4.4 FORMULATIONS

Pharmaceutical compositions for use in accordance with the present invention can be formulated in conventional manner using one or more physiologically acceptable
30 vehicles, carriers or excipients.

Thus, the JNK Inhibitor and optionally a second active agent, and their physiologically acceptable salts and solvates, can be formulated into pharmaceutical compositions for administration by inhalation or insufflation (either through the mouth or the nose) or oral, parenteral or mucosal (such as buccal, vaginal, rectal, sublingual)
35 administration. In one embodiment, local or systemic parenteral administration is used.

5 For oral administration, the pharmaceutical compositions can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (*e.g.*, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (*e.g.*, lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (*e.g.*, magnesium stearate, talc or silica); disintegrants (*e.g.*, potato starch or sodium starch glycolate); or
10 wetting agents (*e.g.*, sodium lauryl sulphate). The tablets can be coated by methods well known in the art. Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can
15 be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (*e.g.*, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (*e.g.*, lecithin or acacia); non-aqueous vehicles (*e.g.*, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (*e.g.*, methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations can also contain
20 buffer salts, flavoring, coloring and sweetening agents as appropriate.

 Preparations for oral administration can be suitably formulated to give controlled release of the JNK Inhibitor.

 For buccal administration the pharmaceutical compositions can take the form of tablets or lozenges formulated in conventional manner.

25 For administration by inhalation, the pharmaceutical compositions for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a
30 pressurized aerosol the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of *e.g.*, gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

 The pharmaceutical compositions can be formulated for parenteral administration
35 by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection

5 can be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The pharmaceutical compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient can be in powder form for constitution with a suitable
10 vehicle, *e.g.*, sterile pyrogen-free water, before use.

The pharmaceutical compositions can also be formulated in rectal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the pharmaceutical
15 compositions can also be formulated as a depot preparation. Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the pharmaceutical compositions can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly
20 soluble derivatives, for example, as a sparingly soluble salt.

The invention also provides that a pharmaceutical composition can be packaged in a hermetically sealed container such as an ampoule or sachette indicating the quantity. In one embodiment, the pharmaceutical composition is supplied as a dry sterilized lyophilized powder or water free concentrate in a hermetically sealed container and can
25 be reconstituted, *e.g.*, with water or saline to the appropriate concentration for administration to a patient.

The pharmaceutical compositions can, if desired, be presented in a pack or dispenser device that can contain one or more unit dosage forms containing the active ingredient. The pack can for example comprise metal or plastic foil, such as a blister
30 pack. The pack or dispenser device can be accompanied by instructions for administration.

In certain preferred embodiments, the pack or dispenser contains one or more unit dosage forms containing no more than the recommended dosage formulation as determined in the *Physician's Desk Reference* (56th ed. 2002, herein incorporated by
35 reference in its entirety).

5 **4.5 ROUTES OF ADMINISTRATION**

Methods of administering a JNK Inhibitor and optionally a second active agent include, but are not limited to, parenteral administration (*e.g.*, intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous), epidural, and mucosal (*e.g.*, intranasal, rectal, vaginal, sublingual, buccal or oral routes). In a specific
10 embodiment, the JNK Inhibitor and optionally the second active agent are administered intramuscularly, intravenously, or subcutaneously. The JNK Inhibitor and optionally the second active agent can also be administered by infusion or bolus injection and can be administered together with other biologically active agents. Administration can be local or systemic. The JNK Inhibitor and optionally the second active agent and their
15 physiologically acceptable salts and solvates can also be administered by inhalation or insufflation (either through the mouth or the nose). In one embodiment, local or systemic parenteral administration is used.

In specific embodiments, it can be desirable to administer the JNK Inhibitor locally to the area in need of treatment. This can be achieved, for example, and not by
20 way of limitation, by local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or
25 former site) of an atherosclerotic plaque tissue.

Pulmonary administration can also be employed, *e.g.*, by use of an inhaler or nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant. In certain embodiments, the JNK Inhibitor can be formulated as a suppository, with traditional binders and vehicles such as triglycerides.

30 In another embodiment, the JNK Inhibitor can be delivered in a vesicle, in particular a liposome (*see* Langer, 1990, *Science* 249:1527-1533; Treat *et al.*, in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; *see* generally *ibid.*).

5 In yet another embodiment, the JNK Inhibitor can be delivered in a controlled release system. In one embodiment, a pump can be used (*see* Langer, *supra*; Sefton, 1987, *CRC Crit. Ref. Biomed. Eng.* 14:201; Buchwald *et al.*, 1980, *Surgery* 88:507; Saudek *et al.*, 1989, *N. Engl. J. Med.* 321:574). In another embodiment, polymeric materials can be used (*see* Medical Applications of Controlled Release, Langer and Wise
10 (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61; *see also* Levy *et al.*, 1985, *Science* 228:190; During *et al.*, 1989, *Ann. Neurol.* 25:351; Howard *et al.*, 1989, *J. Neurosurg.* 71:105). In yet another embodiment, a controlled-release system
15 can be placed in proximity of the target of the JNK Inhibitor, *e.g.*, the liver, thus requiring only a fraction of the systemic dose (*see, e.g.*, Goodson, in Medical Applications of Controlled Release, *supra*, vol. 2, pp. 115-138 (1984)). Other controlled-release systems discussed in the review by Langer, 1990, *Science* 249:1527-1533) can be used.

20 4.6 DOSAGES

 The amount of the JNK Inhibitor that is effective in the treatment, prevention or management of CRPS can be determined by standard research techniques. For example, the dosage of the JNK Inhibitor which will be effective in the treatment, prevention or management of CRPS can be determined by administering the JNK Inhibitor to an
25 animal in a model such as, *e.g.*, the animal models known to those skilled in the art. In addition, *in vitro* assays can optionally be employed to help identify optimal dosage ranges.

 Selection of a particular effective dose can be determined (*e.g.*, via clinical trials) by a skilled artisan based upon the consideration of several factors which will be known
30 to one skilled in the art. Such factors include the disease to be treated or prevented, the symptoms involved, the patient's body mass, the patient's immune status and other factors known by the skilled artisan.

 The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of asbestos-related disease or disorder, and should
35 be decided according to the judgment of the practitioner and each patient's

5 circumstances. Effective doses can be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

The dose of a JNK Inhibitor to be administered to a patient, such as a human, is rather widely variable and can be subject to independent judgment. It is often practical to administer the daily dose of a JNK Inhibitor at various hours of the day. However, in
10 any given case, the amount of a JNK Inhibitor administered will depend on such factors as the solubility of the active component, the formulation used, patient condition (such as weight), and/or the route of administration.

The general range of effective amounts of the JNK Inhibitor alone or in combination with a second active agent are from about 0.001 mg/day to about 1000
15 mg/day, more preferably from about 0.001 mg/day to 750 mg/day, more preferably from about 0.001 mg/day to 500 mg/day, more preferably from about 0.001 mg/day to 250 mg/day, more preferably from about 0.001 mg/day to 100 mg/day, more preferably from about 0.001 mg/day to 75 mg/day, more preferably from about 0.001 mg/day to 50 mg/day, more preferably from about 0.001 mg/day to 25 mg/day, more preferably from
20 about 0.001 mg/day to 10 mg/day, more preferably from about 0.001 mg/day to 1 mg/day. Of course, it is often practical to administer the daily dose of compound in portions, at various hours of the day. However, in any given case, the amount of compound administered will depend on such factors as the solubility of the active component, the formulation used, subject condition (such as weight), and/or the route of
25 administration.

4.7 KITS

The invention provides a pharmaceutical pack or kit comprising one or more containers containing a JNK Inhibitor and optionally one or more second active agents useful for the treatment, prevention or management of CRPS. The invention also
30 provides a pharmaceutical pack or kit comprising one or more containers containing one or more of the ingredients of the pharmaceutical compositions. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human
35 administration; or instructions for the composition's use.

5 The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises a JNK Inhibitor, in one or more containers, and optionally one or more second active agents useful for the treatment, prevention or management of CRPS, in one or more additional containers.


5. **EXAMPLES**

10 The following examples illustrate certain aspects of the invention, but do not limit its scope.

5.1 **JNK INHIBITOR ACTIVITY ASSAYS**

 The ability of a JNK Inhibitor to inhibit JNK and accordingly, to be useful for the treatment, prevention and/or management of an asbestos-related disease or disorder, can
15 be demonstrated using one or more of the following assays.

5.1.1 **Example: Biological Activity of 5-amino-anthra(9,1-*cd*)isothiazol-6-one**



20 **JNK Assay**

 To 10 μ L of 5-amino-anthra(9,1-*cd*)isothiazol-6-one in 20% DMSO/80% dilution buffer containing of 20 mM HEPES (pH 7.6), 0.1 mM EDTA, 2.5 mM magnesium chloride, 0.004% Triton x100, 2 μ g/mL leupeptin, 20 mM β -glycerolphosphate, 0.1 mM sodium vanadate, and 2 mM DTT in water was added 30 μ L of 50-200 ng His6-JNK1,
25 JNK2, or JNK3 in the same dilution buffer. The mixture was pre-incubated for 30 minutes at room temperature. Sixty microliter of 10 μ g GST-c-Jun(1-79) in assay buffer consisting of 20 mM HEPES (pH 7.6), 50 mM sodium chloride, 0.1 mM EDTA, 24 mM magnesium chloride, 1 mM DTT, 25 mM PNPP, 0.05% Triton x100, 11 μ M ATP, and 0.5 μ Ci γ -32P ATP in water was added and the reaction was allowed to proceed for 1
30 hour at room temperature. The c-Jun phosphorylation was terminated by addition of 150

5 μL of 12.5% trichloroacetic acid. After 30 minutes, the precipitate was harvested onto a filter plate, diluted with 50 μL of the scintillation fluid and quantified by a counter. The IC₅₀ values were calculated as the concentration of 5-amino-anthra(9,1-*cd*)isothiazol-6-one at which the c-Jun phosphorylation was reduced to 50% of the control value. Compounds that inhibit JNK preferably have an IC₅₀ value ranging 0.01 - 10 μM in this assay. 5-Amino- anthra(9,1-*cd*)isothiazol-6-one has an IC₅₀ according to this assay of 1
10 μM for JNK2 and 400 nM for JNK3. The measured IC₅₀ value for 5-amino-anthra(9,1-*cd*)isothiazol-6-one, as measured by the above assay, however, shows some variability due to the limited solubility of 5-amino-anthra(9,1-*cd*)isothiazol-6-one in aqueous media. Despite the variability, however, the assay consistently does show that 5-amino-
15 anthra(9,1-*cd*)isothiazol-6-one inhibits JNK. This assay demonstrates that 5-amino-anthra(9,1-*cd*)isothiazol-6-one, an illustrative JNK Inhibitor, inhibits JNK2 and JNK3 and, accordingly, is useful for the treatment, prevention and/or management of an asbestos-related disease or disorder.

20 Selectivity For JNK:

5-Amino-anthra(9,1-*cd*)isothiazol-6-one was also assayed for its inhibitory activity against several protein kinases, listed below, using techniques known to those skilled in art (*See, e.g., Protein Phosphorylation, Sefton & Hunter, Eds., Academic Press, pp. 97-367, 1998*). The following IC₅₀ values were obtained:

25	<u>Enzyme</u>	<u>IC₅₀</u>
	p38-2	>30,000 nM
	MEK6	>30,000 nM
	LKK1	>30,000nM
	IKK2	>30,000nM

30 This assay shows that 5-amino-anthra(9,1-*cd*)isothiazol-6-one, an illustrative JNK Inhibitor, selectively inhibits JNK relative to other protein kinases and, accordingly, is a selective JNK Inhibitor. Therefore, 5-amino-anthra(9,1-*cd*)isothiazol-6-one, an illustrative JNK Inhibitor, is useful for the treatment, prevention and/or management of
35 an asbestos-related disease or disorder.

5

Jurkat T-cell IL-2 Production Assay:

Jurkat T cells (clone E6- 1) were purchased from the American Type Culture Collection of Manassas, VA and maintained in growth media consisting of RPMI 1640 medium containing 2 mM L-glutamine (commercially available from Mediatech Inc. of Herndon, VA), with 10% fetal bovine serum (commercially available from Hyclone Laboratories Inc. of Omaha, NE) and penicillin/streptomycin. All cells were cultured at 37°C in 95% air and 5% CO₂. Cells were plated at a density of 0.2 x 10⁶ cells per well in 200 µL of media. Compound stock (20 mM) was diluted in growth media and added to each well as a 10x concentrated solution in a volume of 25 µL, mixed, and allowed to pre-incubate with cells for 30 minutes. The compound vehicle (dimethylsulfoxide) was maintained at a final concentration of 0.5% in all samples. After 30 minutes the cells were activated with PMA (phorbol myristate acetate, final concentration 50 ng/mL) and PHA (phytohemagglutinin, final concentration 2 µg/mL). PMA and PHA were added as a 10x concentrated solution made up in growth media and added in a volume of 25 µL per well. Cell plates were cultured for 10 hours. Cells were pelleted by centrifugation and the media removed and stored at -20°C. Media aliquots are analyzed by sandwich ELISA for the presence of IL-2 as per the manufacturers instructions (Endogen Inc. of Woburn, MA). The IC₅₀ values were calculated as the concentration of 5-amino-anthra(9,1-*cd*)isothiazol-6-one at which the IL-2 production was reduced to 50% of the control value. Compounds that inhibit JNK preferably have an IC₅₀ value ranging from 0.1 - 30 µM in this assay. 5-Amino-anthra(9,1-*cd*)isothiazol-6-one has an IC₅₀ of 30 µM. The measured IC₅₀ value for 5-amino-anthra(9,1-*cd*)isothiazol-6-one, as measured by the above assay, however, shows some variability due to the limited solubility of 5-amino-anthra(9,1-*cd*)isothiazol-6-one in aqueous media. Despite the variability, however, the assay consistently does show that 5-amino-anthra(9,1-*cd*)isothiazol-6-one inhibits JNK.

This assay shows that 5-amino-anthra(9,1-*cd*)isothiazol-6-one, an illustrative JNK Inhibitor, inhibits IL-2 production in Jurkat T-cells and accordingly inhibits JNK. Therefore, 5-amino-anthra(9,1-*cd*)isothiazol-6-one, an illustrative JNK Inhibitor, is useful for the treatment, prevention and/or management of an asbestos-related disease or disorder.

5 [³H]Dopamine Cell Culture Assay:

Cultures of dopaminergic neurons were prepared according to a modification of the procedure described by Raymon and Leslie (*J. Neurochem.* 62:1015-1024, 1994). Time-mated pregnant rats were sacrificed on embryonic day 14 - 15 (crown rump length 11 - 12 mm) and the embryos removed by cesarean section. The ventral mesencephalon,
10 containing the dopaminergic neurons, was dissected from each embryo. Tissue pieces from approximately 48 embryos were pooled and dissociated both enzymatically and mechanically. An aliquot from the resulting cell suspension was counted and the cells were plated in high glucose DMEM/F12 culture medium with 10% fetal bovine serum at a density of 1×10^5 cells/well of a Biocoat poly-D-lysine-coated 96-well plate. The day
15 following plating was considered 1 day *in vitro* (DIV). Cells were maintained in a stable environment at 37°C, 95% humidity, and 5% CO₂. A partial medium change was performed at 3 DIV. At 7 DIV, cells were treated with the neurotoxin, 6-hydroxydopamine (6-OHDA, 30 μ M) in the presence and absence of 5-amino-anthra(9,1-*cd*)isothiazol-6-one. Cultures were processed for [³H]dopamine uptake
20 hours later.

[³H]Dopamine uptake is used as a measure of the health and integrity of dopaminergic neurons in culture (Prochiantz et al., *PNAS* 76: 5387-5391, 1979). It was used in these studies to monitor the viability of dopaminergic neurons following exposure to the neurotoxin 6-OHDA. 6-OHDA has been shown to damage
25 dopaminergic neurons both *in vitro* and *in vivo* and is used to model the cell death observed in Parkinson's disease (Ungerstedt, U., *Eur. J. Pharm.*, 5 (1968) 107-110 and Hefti et al., *Brain Res.*, 195 (1980) 123-137). Briefly, cells treated with 6-OHDA in the presence and absence of 5-amino-anthra(9,1-*cd*)isothiazol-6-one were assessed in the uptake assay 22 hrs after exposure to 6-OHDA. Culture medium was removed and
30 replaced with warm phosphate buffered saline (PBS) with calcium and magnesium, 10 μ M pargyline, 1 mM ascorbic acid, and 50 nM [³H]dopamine. Cultures were incubated at 37°C for 20 min. Radioactivity was removed and the cultures were washed 3x with ice cold PBS. To determine the intracellular accumulation of [³H]dopamine, cells were lysed with M-PER detergent and an aliquot was taken for liquid scintillation counting.
35 The measured effect of 5-amino-anthra(9,1-*cd*) isothiazol-6-one on the intracellular

5 accumulation of [^3H]dopamine, as measured by the above assay, however, shows some variability due to the limited solubility of 5-amino-anthra(9,1-*cd*)isothiazol-6-one in aqueous media. Despite the variability, however, the assay consistently does show that 5-amino-anthra(9,1-*cd*)isothiazol-6-one protects rat ventral mesencephalan neurons from the toxic effects of 6-OHDA. Accordingly, 5-amino-anthra(9,1-*cd*)isothiazol-6-one, an
10 illustrative JNK Inhibitor, is useful for the treatment, prevention and/or management of an asbestos-related disease or disorder.

Brain-Blood Plasma Distribution of 5-amino-anthra(9,1-*cd*)isothiazol-6-one *In Vivo*

5-Amino-anthra(9,1-*cd*)isothiazol-6-one was administered intravenously (10
15 mg/kg) into the veins of Sprague-Dawley rats. After 2 hr, blood samples were obtained from the animals and their vascular systems were perfused with approximately 100 mL of saline to rid their brains of blood. The brains were removed from the animals, weighed, and homogenized in a 50 mL conical tube containing 10 equivalents (w/v) of methanol/saline (1:1) using a Tissue Tearer (Fischer Scientific). The homogenized
20 material was extracted by adding 600 μL of cold methanol to 250 μL of brain homogenate vortexed for 30 sec and subjected to centrifugation for 5 min. After centrifugation, 600 μL of the resulting supernatant was transferred to a clean tube and evaporated at room temperature under reduced pressure to provide a pellet. The resulting pellet was reconstituted in 250 μL of 30% aqueous methanol to provide a brain
25 homogenate analysis sample. A plasma analysis sample was obtained using the brain homogenate analysis sample procedure described above by substituting plasma for brain homogenate. Standard plasma samples and standard brain homogenate samples containing known amounts of 5-amino-anthra(9,1-*cd*)isothiazol-6-one were also prepared by adding 5 μL of serial dilutions (50:1) of a solution of 5-amino-anthra(9,1-
30 *cd*)isothiazol-6-one freshly prepared in cold ethanol to 250 μL of control rat plasma (Bioreclamation of Hicksville, NY) or control brain homogenate. The standard plasma samples and standard brain homogenate samples were then subjected to the same extraction by protein precipitation, centrifugation, evaporation, and reconstitution procedure used for the brain homogenate to provide brain homogenate standard analysis
35 samples and plasma standard analysis samples. The brain homogenate analysis samples, plasma analysis samples, and standard analysis samples were analyzed and compared

5 using HPLC by injecting 100 μ L of a sample onto a 5 μ m C-18 Luna column (4.6 mm x 150 mm, commercially available from Phenomenex of Torrance, CA) and eluting at 1 mL/min with a linear gradient of 30% aqueous acetonitrile containing 0.1% trifluoroacetic acid to 90% aqueous acetonitrile containing 0.1% trifluoroacetic acid over 8 minutes and holding at 90% aqueous acetonitrile containing 0.1% trifluoroacetic acid
10 for 3 min. with absorbance detection at 450 nm. Recovery of 5-amino-anthra(9,1-*cd*)isothiazol-6-one was $56 \pm 5.7\%$ for plasma and $42 \pm 6.2\%$ for the brain. The concentration of 5-amino-anthra(9,1-*cd*) isothiazol-6-one in the brain and plasma was determined by comparing HPLC chromatograms obtained from the brain homogenate analysis samples and plasma analysis samples to standard curves constructed from
15 analysis of the brain homogenate standard analysis samples and the plasma standard analysis samples, respectively. Results from this study show that 5-amino-anthra(9,1-*cd*)isothiazol-6-one, following intravenous administration, crosses the blood-brain barrier to a significant extent. In particular, brain-drug concentrations were approximately 65 nmole/g and plasma concentrations were approximately 7 μ M at 2 hr post-dose, resulting
20 in a brain-plasma concentration ratio of approximately 9-fold (assuming 1 g of brain tissue is equivalent to 1 mL of plasma). This example shows that 5-amino-anthra(9,1-*cd*)isothiazol-6-one, an illustrative JNK Inhibitor, has enhanced ability to cross the blood-brain barrier. In addition, this example shows that the JNK Inhibitors, in particular 5-amino-anthra(9,1-*cd*)isothiazol-6-one, can cross the blood-brain barrier
25 when administered to a patient.

5.2 CLINICAL STUDIES IN MESOTHELIOMA PATIENTS

Clinical trials with the administration of 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene and vinorelbine are conducted in patients with malignant mesothelioma and malignant pleural effusion mesothelioma syndrome.
30 Patients receive 1-1000 mg per day, 1-500 mg per day, 1-250 mg per day or 1-100 mg per day of 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene for 10, 20, 30, 60, 90, 120 or 200 days. Patients who experience clinical benefit are permitted to continue on treatment.

Other clinical studies are performed using 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene in unresectable or relapsed mesothelioma
35

5 patients that have not responded to conventional therapy. In one embodiment, 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene is administered in an amount of 1-1000 mg per day, 1-500 mg per day, 1-250 mg per day or 1-100 mg per day, to the patients for 10, 20, 30, 60, 90, 120 or 200 days. It is understood that other preferred embodiments are when 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-
10 piperidylethoxy)benzene is administered at about 75-900 mgs/day or a greater dose, or at about 1.5 to 2.5 times the daily dose every other day. The studies in mesothelioma patients treated with a JNK Inhibitor will show that the drug has therapeutic benefit in this disease.

It will be appreciated that, although specific embodiments of the invention have
15 been described herein for purposes of illustration, the invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed. These embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein
20 will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

A number of references have been cited, the entire disclosure of which are incorporated herein by reference in their entirety.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.